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ABSTRACT 
 
Introduction: A westernized diet rich in saturated fats and sugars, together with a sedentary 
lifestyle, has contributed to the dramatic increase in obesity during the last decade (Zimmett 
et al, 2001; Wild et al, 2004).   Obesity is associated with dyslipidemia and insulin resistance 
which are major risk factors for the development of type 2 diabetes (T2D) (Zimmet et al, 2001, 
Kahn et al, 2006; Schröder et al, 2007).  High-fat feeding in rodents induces symptoms similar 
to the human metabolic syndrome without progression to T2D (Woods et al, 2002; Weir and 
Bonner-Weir, 2007).  The addition of fructose to a high-fat diet exacerbates the insulin 
resistance and leads to impaired pancreatic function of insulin secretion and glucose 
intolerance (Basciano et al, 2005; Stanhope et al, 2009).   
Aims: The aim of this study was to establish the effect of a high-fat and sucrose/fructose diet 
on glucose metabolism, the development of insulin resistance and β-cell dynamics. 
 Methods: Weanling Wistar rats were randomized into two study groups; study one over an 
experimental period for three months and study two for twelve months.  Each study consisted 
of a control group that received standard rat chow and water; and two experimental groups 
receiving either a high-fat diet and water (HFD) or a café diet consisting of HFD with the 
addition of 15% sucrose/fructose (CFD).  Fasting glucose and insulin concentrations, 
intravenous glucose tolerance test (IVGTT), glucose stimulated insulin secretion rates and 2-
deoxy-[3H]-D-glucose uptake in muscle, liver and fat were measured.  The pancreata were 
harvested for immunohistochemical labeling of β-cells (insulin), α-cells (glucagon), GLUT2 
(glucose transport) and MIB5 (proliferation).  Samples of the pancreata were also collected for 
electron microscopy. 
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Results and discussion: Feeding Wistar rats a CFD induced obesity, insulin resistance and 
glucose intolerance.  By twelve months the rats had an impaired glucose response with 
increased IVGTT peak values, area under the curve (AUC) values and glucose clearance 
rates.  Concomitantly, the glucose stimulated insulin secretion rate (GS-ISR) was attenuated.  
Stimulated glucose disposal as measured by 2-deoxy-[3H]-D-glucose uptake was reduced in 
muscle and adipose tissue at three months.  By twelve months, due to the age of the rats, 
stimulated glucose uptake declined compared to three months with no difference between 
groups.  After three months the diets had no observable effect on the islets using light 
microscopy.  However, by twelve months morphological changes were observed in both the 
HFD and CFD groups.  In the HFD group large hypertrophied irregular islets with fibrous 
changes were observed.  In the CFD group these morphological changes were more 
prominent with fibrous segregation and disruption of the normal endocrine arrangement.  In 
addition, the presence of inflammatory cells within the affected islets is consistent with T2D. 
Conclusion:  High-fat diet fed to Wistar rats induced obesity, abdominal adiposity and insulin 
resistance.  The addition of sucrose/fructose to a high-fat diet exacerbated the insulin 
resistance and resulted in glucose intolerance and mild hyperglycemia.  Morphological 
changes in the large islets were observed which are consistent with the development of T2D.   
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ABSTRAK 
Inleiding: ‘n Verwesterde dieët, ryk aan versadigde vette en suikers tesame met „n passiewe 
lewenstyl, het bygedra tot die dramatiese verhoging in vetsug gedurende die laaste dekade 
(Zimmett et al, 2001; Wild et al, 2004).   Vetsug word met dislipidemie en 
insulienweerstandigheid geassosieer wat hoof risikofaktore is vir die ontwikkeling van tipe 2 
diabetes (T2D) (Zimmet et al, 2001; Kahn et al, 2006; Schröder et al, 2007).  Hoë-vet voeding 
in knaagdiere induseer simptome soortgelyk aan menslike metaboliese sindroom sonder die 
ontwikkeling van T2D (Woods et al, 2002; Weir and Bonner-Weir, 2007).  Die byvoeging van 
fruktose tot „n hoë-vet dieët vererger insulienweerstandigheid en lei tot verswakte pankreas 
funksie, insuliensekresie en glukoseintoleransie (Basciano et al, 2005; Stanhope et al, 2009).   
Doelwitte: Die doelwitte van die studie was om die effek van hoë-vet en sukrose/fruktose 
voeding op glukosemetabolisme, die ontwikkeling van insulienweerstandigheid en β-sel 
dinamika te bepaal. 
 Metodes: Gespeende Wistar rotte was in twee groepe gerandomiseer; studie een oor ŉ 
tydperk van drie maande en studie twee oor ŉ tydperk van twaalf maande onderskeidelik.  
Elke studie het „n kontrole groep met standard rot kos en water (control); en twee 
experimentele dieëte wat of ŉ hoë-vet dieët en water (HFD) of „n kafeedieët groep wat die 
HFD met die byvoeging van 15% sukrose/fruktose in hul drink water (CFD) ontvang.  
Fastende glukose and insulien, binneaarse glukose toleransie toets (IVGTT), glukose 
gestimuleerde insulien sekresie tempo en 2-deoxi-[3H]-D-glukose opname in spier, lewer en 
vet is gebruik om die effek van die dieët op glukosemetabolisme te bepaal.  Die pankreata is 
uitgehaal vir immunohistochemiese identifisering van β-selle (insulien), α-selle (glukagoon), 
GLUT2 (glukose transport) en MIB5 (proliferasie).  Monsters van die pankreata was ook vir 
elektronmikroskopie versamel. 
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Resultate en bespreking: Voeding van ŉ CFD aan Wistar rotte induseer vetsug, 
insulienweerstandigheid en glukose-intoleransie   Teen twaalf maande toon die rotte „n 
verswakte response tot glukose met verhoogde IVGTT piekwaardes, AUC waardes en 
glukose opriumingswaardes.   Tenselfdetyd is die glukose gestimuleerde insuliensekresie 
tempo (GS-ISR) ook verswak.  Gestimuleerded glukose opruiming, soos deur 2-deoxi-[3H]-D-
glukose opname bepaal, was verlaag in spier en vetweefsel teen drie maande.  Teen twaalf 
maande, weens die ouderdom van die rotte, is die gestimuleerde glucose opname verlaag in 
vergelyking met drie maande sonder „n verskil tussen groepe.  Na drie maande kon geen 
sigbare morfologiese verskille met ligmikroskopie tussen die dieëte waargeneem word nie.  
Teen twaalf maande is morfologiese verskille waargeneem in beide die HFD en die CFD 
groepe.  In die HFD groep is groot hipertrofiese onreëlmatige eilande met fibrotiese 
verandering waargeneem.  In die CFD groep was die morfologiese verandering meer 
gevorder met fibrotiese onderverdeling en ontwrigting van die normale endokriene 
rangskikking.  Die teenwoordigheid van inflammatoriese selle in die geaffekteerde eilande is 
verenigbaar met T2D. 
Afleiding:  Die voer van „n hoë-vet dieët aan Wistar rotte veroorsaak vetsug, abdominale 
adipositeit en insulienweerstandigheid.  Die byvoeging van sukrose/ fruktose tot die hoë-vet 
dieët vergerger die insulienweerstandigheid en veroorsaak glukoseintoleransie en matige 
hiperglukemie.  Morfologiese veranderings in die groter eilande was verenigbaar met T2D.   
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INTRODUCTION 
The incidence of obesity has risen to alarming levels, with an estimate of 300 million people 
affected worldwide (Schröder et al, 2007).  In addition the prevalence of diabetes has also 
increased dramatically, with an estimate of 150 million people in 2000, likely to double by 
2025.  This places a huge burden on available health resources especially in developing 
countries (Prentki and Nolan, 2006; Schröder et al, 2007).  A close relationship exists 
between obesity, the development of metabolic syndrome and T2D (Zimmet et al, 2001; 
Schröder et al, 2007).  A westernized lifestyle and diet with high saturated fat content has 
been shown to be the main contributing factors to increasing obesity, developing insulin 
resistance and T2D (Zimmet et al, 2001; Cerf, 2007; Thévenod, 2008).   
In order to maintain normoglycemia, due to increased body mass, the body compensates by 
hypersecretion of insulin and increased insulin synthesis resulting in increased β-cell mass 
(Prentki and Nolan, 2006).  The larger demand for insulin eventually results in β-cell 
dysfunction and loss of β-cells due to apoptosis (Butler et al, 2003).   
High-fat feeding of rats, not genetically predisposed to developing diabetes, induces obesity 
and insulin resistance without the progression to T2D (Woods et al, 2002; Weir and Bonner-
Weir, 2007).  The addition of sucrose/fructose exacerbates the effect of high-fat feeding by 
increasing dyslipidemia, further decreasing insulin sensitivity and increasing visceral adiposity 
(Basciano et al, 2005; Stanhope et al, 2009).   
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LITERATURE REVIEW  
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1.1 The pancreas and β-cells 
The pancreas is a digestive organ that produces and secretes digestive fluids containing 
various digestive enzymes via its exocrine acinar cells and ducts.  It contains endocrine cells 
that appear as discrete cell clusters called islets containing a heterogeneous population of 
neuroendocrine cells which produce four major hormones namely insulin (secreted by the β-
cells), glucagon (secreted by the α-cells), somatostatin (secreted by the δ-cells) and 
pancreatic poly-peptide (PP-cells) (Ganong, 1989; Stevens and Lowe, 2005).  Insulin and 
glucagon have important functions in the metabolism of carbohydrates, proteins and fats and 
plays a major role in maintenance of glucose homeostasis (Ganong, 1989).   
In 1939 H.P. Himsworth observed that certain patients were more sensitive to the 
hypoglycemic effect of insulin than others that required higher doses of insulin (Reaven, 
2005). These observations were the first reference to the concept of impaired insulin action or 
insulin resistance (Reaven, 2005) which is a crucial factor in the development and 
pathogenesis of T2D (WHO, 2006) 
 
1.2 Obesity 
Obesity is defined as an excessive accumulation of body fat to an extent where it may have 
adverse effects on the health of the individual (WHO, 2006; Galic et al, 2010).  The cause of 
obesity is a prolonged imbalance where energy intake levels exceed energy expenditure 
which results in lipids being stored as excess fat (Speakman et al, 2007).  According to the 
WHO, obesity is defined as a body mass index (BMI) equal to or more than 30 kg/m2 (WHO, 
2006).  Body mass index is calculated as the weight in kilograms divided by the square root of 
the height in meters of an individual.     
Worldwide, the prevalence of obesity has risen to alarming levels, with approximately 300 
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million people affected (Schröder, 2007).  The WHO projects that approximately 2.3 billion 
adults will be overweight and more than 700 million adults will be obese in 2015 (WHO, 
2006).   
In developing countries, including South Africa, a migration from a traditional rural to a 
westernized diet is associated with an increased consumption of energy-dense foods 
containing refined carbohydrates, sugars and high saturated fats (Cerf, 2007).  A general 
decline in physical activity further leads to an increase in body mass (Schröder et al, 2007).  A 
close relationship exists between obesity and the development of T2D with the common 
cause being unhealthy diets (Schröder, 2007) and sedentary lifestyle (Zimmet et al, 2001).   
 
 
Figure 1: Schematic diagram depicting the adverse effects of obesity  
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Several other adverse health consequences of obesity (Fig 1) include insulin resistance, 
coronary heart disease, hypertension, fetal defects due to maternal obesity and certain types 
of cancers such as endometrial, breast (in postmenstrual woman) and colon (WHO, 2000).  
The accumulation of lipids in adipose tissue plays an important role in the regulation of fatty 
acid metabolism where in periods of calorie abundance it stores free fatty acid (FFA) as 
triglycerides and can therefore release them into the circulation when there is a shortage of 
energy (Galic et al, 2010).  The increased storage of fatty acids in expanded adipose tissue 
mass is closely related to the development of insulin resistance in insulin sensitive tissues 
such as skeletal muscle and liver (Galic et al, 2010).   
The relationship between a diet with high saturated fat content and obesity, insulin resistance 
and T2D is well established (Zimmet et al, 2001; Cerf, 2007; Thévenod, 2008).  In the young 
and adult populations, the increase in the consumption of fructose has been identified as a 
major cause of obesity.  The consumption of fructose with a high-fat diet synergistically 
exacerbates insulin resistance and dyslipidemia (Basciano et al, 2005).   
Many genetic and diet-induced obesity (DIO) animal models have been developed to study 
the physiology and genetic basis of obesity.  Diet-induced obesity in animal models using 
high-fat feeding closely resembles the human development of the metabolic syndrome 
(Buettner et al, 2006).  In non-genetic predisposed rodents the extent of obesity depends on 
the specific rodent strain in combination with the diet regime followed.  High-fat fed Wistar rats 
and C57BL/6J mice develop obesity and insulin resistance while 129S6 and A/J mice do not 
(Buettner et al, 2006).   
In the genetically pre-disposed leptin deficient obese mouse (ob/ob) the mutation generates 
massive obesity.  This defect results in a premature stop codon in the gene expressed almost 
exclusively in adipocytes (Speakman et al, 2007; Galic et al, 2010).  Leptin has been 
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identified as a signal of adipose tissue storage; in obesity leptin concentrations are increased 
(Galic et al, 2010). 
 
1.3 Metabolic syndrome (Syndrome X) 
The concept of Syndrome X, first introduced in the Banting Lecture 1988 (Reaven, 1988), 
included individuals that were insulin resistant, compensatory hyperinsulinemic, glucose 
intolerant and exhibited increased plasma triglycerides and decreased high density lipoprotein 
(HDL) cholesterol.  The name Syndrome X originates from the algebraic term, the letter X 
which equals the unknown because the association between insulin resistance and the 
association with its risk factors for cardio-vascular diseases (CVD) was unknown (Reaven, 
2005).  The term Syndrome X has been replaced by insulin resistance syndrome which 
describes an array of abnormal and clinical syndromes associated with insulin resistance (Fig 
2) (Reaven, 2005). 
 
Figure 2: Schematic diagram depicting the manifestations of the Insulin Resistance 
Syndrome (Reaven, 2005) 
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The metabolic syndrome comprises a cluster of metabolic disorders which includes increased 
body mass, abdominal obesity, insulin resistance, hyperglycemia, dyslipidaemia and 
hypertension (Pittas et al, 2004; Després and Lemieux, 2006; Fulop et al, 2006; Azevedo et 
al, 2009).  These are all risk factors for the development of T2D and CVD and are all major 
causes of morbidity and mortality (Azevedo et al, 2009).   
Abdominal obesity is the major determinant and most prevalent manifestation of the metabolic 
syndrome (Després and Lemieux, 2006; Fulop et al, 2006; Monteiro and Azevedo, 2010).  
The increase in abdominal obesity leads to adipocyte hypertrophy which causes these cells to 
rupture and evoke an inflammatory response (Fulop et al, 2006; Monteiro and Azevedo, 
2010) which results in a chronic low-grade inflammation (Boden, 2006).  Inflammation is 
driven by adipokines and cytokines (Fig 3) secreted by these hypertrophic, adipocytes and 
macrophages respectively (Fulop et al, 2006).  Visceral adipose tissue in particular is able to 
secrete adipokines with endocrine, paracrine and autocrine activity able to induce insulin 
resistance, inflammation, dyslipidemia and endothelial dysfunction (Fulop et al, 2006).  Some 
adipokines e.g. adiponectin, has protective effects against the development of metabolic 
syndrome (Fulop et al, 2006).  
 
 
Figure 3: Obesity mediated inflammatory response (Adapted from Fulop et al, 2006) 
 
Visceral adipose cell 
Pro-inflammatory 
cytokines: 
TNF-α 
IL-1 
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Adiponectin 
Leptin 
Resistin 
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Pro-thrombotic molecules: 
PAI-1 
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Excess fat deposition in other vital organs, such as the liver, has severe consequences on 
insulin resistance (Monteiro and Azevedo, 2010).  The anatomic distribution of adipose tissue 
potentially has a major effect on insulin sensitivity.  The accumulation of abdominal visceral 
fat correlates strongly with the development of insulin resistance (Fulop et al, 2006).  In 
contrast, subcutaneous adipose tissue, which has a large fat storage capacity, acts as a 
reservoir and has a protective effect against the development of metabolic syndrome 
(Monteiro and Azevedo, 2010).  Viscerally obese individuals represent a sub-group with 
severe insulin resistance.  Insulin resistant, visceral adipocytes cause increased release of 
FFA from the visceral tissue to the liver resulting in lipoprotein and lipid metabolism 
disturbances (Fulop et al, 2006).  This leads to liver insulin resistance, glucose intolerance, 
increased triglycerides and LDL- cholesterol which are common features of viscerally obese 
individuals.  In addition to its fat storage function, adipose tissue can be regarded as an 
endocrine organ due to its ability to release adipocyte-specific factors such as adipokines 
(Galic et al, 2010).  In addition to adipokines, the visceral adipocytes and or infiltrating 
macrophages secrete pro-inflammatory cytokines of which tumor necrosis factor α (TNFα) is 
the most important.  TNFα modulates the expression of leptin and interleukin- 6 (IL-6) while 
suppressing adiponectin thereby linking visceral obesity with insulin resistance and metabolic 
syndrome (Fulop et al, 2006).   
 
1.4 Insulin Signaling  
Insulin is a peptide hormone secreted in response to increased circulating glucose levels by 
the β-cell in the pancreas (Pessin and Saltiel, 2000; Chakraborty, 2006).  Insulin is essential 
in regulating carbohydrate, lipid and protein metabolism and the maintenance of whole-body 
glucose homeostasis (Pessin and Saltiel, 2000; Chakraborty, 2006; Sesti, 2006).  Insulin 
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induces increased lipid synthesis in the liver and fat cells and decreases lipolysis from 
triglycerides in fat and muscle tissue (Chakraborty, 2006).   
 
Figure 4: Insulin signaling pathway (Adapted from Choi and Kim, 2010) 
Insulin-stimulated glucose uptake in muscle and fat is initiated by the binding of insulin to the 
insulin receptor (α-subunit) on the cell surface, resulting in autophosphorylation of multiple 
tyrosine residues of the insulin receptor β-subunit in the cytoplasm (Fig 4).  This results in 
tyrosine phosphorylation of insulin receptor substrates (IRS1 and IRS2).  Phosphorylation of 
the IRS proteins facilitates the binding of Src homology 2 (SH2) domain (p85 subunit) of 
phosphoinositide 3-kinase (PI3K).  Activation of PI3K   initiates the PI3K/Akt pathway which 
results in glucose transporter four (GLUT4) translocation from a cytoplasmic pool to the 
plasma membrane.  Glucose is then actively transported into the cell via GLUT4 located in 
the plasma membrane.   
 
 
 
 
Figure 4: Insulin signaling pathway (Adapted from Choi and Kim, 2010) 
Plasma membrane 
Insulin 
receptor 
α-subunit 
PI3K 
Insulin 
receptor 
β-subunit 
Glucose 
IRS1/2 
Insulin 
9 
 
The PI3K/Akt pathway plays a pivotal role in insulin signaling and glucose transport via 
GLUT4.  In T2D, PI3K activity decreases in skeletal muscle providing evidence that deficient 
insulin signaling could result in impaired GLUT4 mediated glucose transport and insulin 
resistance (Choi and Kim, 2010).  Similarly Akt in muscle from non-obese T2D while Akt2 
phosphorylation is impaired from adipocytes in obese type 2 diabetics (Choi and Kim, 2010).   
Increased concentrations of FFA, directly or in combination, with inflammatory cytokines e.g 
TNF-α cause several defects in insulin signaling (Griffin et al, 1999; Yu et al, 2002).  Resulting 
in serine phosphorylation, instead of tyrosine phosphorylation, of IRS1.  This causes IRS 
protein degradation or IRS protein inhibiting the activation of the PI3K/Akt pathway (Yu et al, 
2002; Sesti, 2006).  Therefore GLUT4 translocation is inhibited and glucose transport into the 
cell is attenuated (Sesti, 2006).   
 
1.5 Insulin Resistance 
Insulin resistance is defined as the inability of target organs, liver, muscle and fat tissues, to 
respond effectively to insulin stimulation (Pittas et al, 2004; Chakraborty, 2006).  Therefore 
during the development of insulin resistance the body compensates by increasing insulin 
secretion (Pittas et al, 2004).  To compensate for the ever increasing demand for insulin, 
pancreatic β-cell mass increases either by β-cell hypertrophy or β-cell hyperplasia (Weir and 
Bonner-Weir, 2007; Fujitani et al, 2010).  The balance between islet β-cell hypertrophy, β-cell 
proliferation and β-cell apoptosis directly determines β-cell mass (Weir et al, 2001).  The 
capacity of the functional β-cell mass to increase in response to insulin resistance is crucial to 
prevent the development of T2D (Weir and Bonner-Weir, 2007).  A fundamental aspect of the 
pathogenesis of diabetes is the failure of the pancreatic β-cells to synthesize and secrete 
sufficient amounts of insulin to maintain normoglycemia (Weir et al, 2001).  
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The assessment of insulin resistance using HOMA-IR is a tool commonly used for a crude 
measurement of insulin resistance (Bonora et al, 2002). It is less invasive, inexpensive 
therefore a more efficient way of assessing insulin resistance when compared to glucose 
clamp tests (Kang et al, 2005).  HOMA-IR  limitations are to be considered especially in 
subjects with low BMI, low β-cell function, high fasting glucose concentrations in T2D patients 
(Kang et al, 2005) and older people (Chang et al, 2006).   
 
1.6 β-cell mass and dynamics 
There are four major mechanisms involved in the regulation of β-cells mass i.e. neogenesis, 
size modification, replication and apoptosis (Dor et al, 2004; Halban, 2004; Bonner-Weir et al, 
2005; Rhodes, 2005; Marchetti et al, 2008).  β-cell mass is represented by the sum of 
neogenesis, replication and size minus the rate of apoptosis at any given time (Rhodes, 2005; 
Marchetti et al, 2008; Karaca et al, 2009).     
 
A key issue in the understanding of the pathogenesis of diabetes is the regulation of β-cell 
mass (Bouwens and Rooman, 2005).  At birth, the number of β-cells present is mainly 
generated by proliferation and differentiation of pancreatic progenitor cells through 
neogenesis (Bouwens and Rooman, 2005; Rhodes, 2005; de Koning, 2008; Marchetti et al, 
2008).  After birth, a proportion of cycling β-cells can expand in cell number to compensate for 
an increased insulin demand mainly by β-cell proliferation and to a lesser extent by β-cell 
neogenesis (Bouwens and Rooman, 2005).  β-cell proliferation is increased and the rate of 
apoptosis is low which creates the increased β-cell growth early in life.  These growth 
mechanisms adjust during childhood and adolescence which creates equilibrium of sufficient 
β-cell mass thought adulthood (Marchetti et al, 2008).  With aging, the β-cell mass decreases 
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as the rate of apoptosis outweigh proliferation (Rhodes, 2005; Marchetti et al, 2008).  This 
could explain why the elderly are more prone to develop T2D (Rhodes, 2005). 
 
The lifespan of β-cells in rodents is estimated at approximately 60 days with approximately 
0.5% of adult β-cells undergoing apoptosis (Rhodes, 2005).  Normally the resultant loss of β-
cells is compensated by β-cell replication (Rhodes, 2005).  β-cell failure occurs when the 
critical β-cell mass declines to such an extent that the remaining β-cells are unable to 
compensate for the insulin requirements (Prentki et al, 2006).  The most likely mechanisms 
involved in early β-cell mass reduction includes mitochondrial dysfunction, oxidative stress, 
endoplasmic reticulum stress, dysfunctional triglycerides, FFA and glucolipotoxicity (Prentki et 
al, 2006).  The subsequent development of hyperglycemia includes additional processes 
linked to glucotoxicity including islet inflammation, O-linked glycosylation and amyloid 
deposition that accelerates β-cell apoptosis (Prentki et al, 2006).  Amylin (islet amyloid poly-
peptide- IAPP) co-secreted with insulin, has been implicated in β-cell failure and is the pre-
curser of amyloid deposition in T2D (DeFronzo, 2004).  Elevated plasma IAPP levels have 
been associated with T2D patients, obese glucose intolerant subjects and in animal models of 
diabetes (DeFronzo, 2004).  It is suggested that elevated levels of FFA and amylin 
hypersecretion as is found in insulin resistance acts synergistically to impair β-cell function 
and cause β-cell injury (DeFronzo, 2004).   
  
Glucotoxicity is associated with hyperglycemia that causes β-cell desensitization to glucose 
and increased apoptosis (Marchetti et al, 2008).  Clinical evidence has proven that lowered 
serum glucose concentrations in T2D patients can cause an increase in their acute insulin 
response to glucose (Marchetti et al, 2008).  Glucotoxicity is associated with inflammatory 
cytokines, like interleukin one beta (IL-1β), secreted by human islets, in the presence of high 
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glucose concentrations which can mediate β-cell apoptosis (Maedler et al, 2002).   
In insulin resistant and T2D patients, dyslipidemia and resultant lipotoxicity, associated with 
the accumulation of FFA and their metabolic products have a deleterious effect on β-cells 
(Maedler et al, 2002).  In addition lipotoxicity alters insulin signaling in the liver and skeletal 
muscle thereby contributing to whole body insulin resistance and deterioration of glucose 
tolerance (Galgani et al, 2008).  A study inducing glucolipotoxicity in Wistar rats caused 
insulin resistance at six months but not in two month old rats which suggests that older 
animals should be used in studies of diet induced insulin resistance and which closely mimic 
typical T2D (Fontés et al, 2010).   
 
1.7 Diet-induced type 2 diabetic animal models 
Animal models in the study of diabetes are advantageous and offer useful insights into the 
mechanisms of human diabetes (Srinivasan and Ramarao, 2007).  Rodent models fed a high-
fat diet have contributed significantly to our understanding of the pathophysiology of insulin 
resistance.  According to Buettner et al, the first description of a high-fat diet used to induce 
obesity via nutritional intervention was performed by Masek and Fabry in 1959 (Buettner et al, 
2006).  Different types of fat in high-fat diets have varying effects on glucose metabolism in 
Wistar rats.  Lard, rich in polyunsaturated fatty acids, and olive oil, rich in monounsaturated 
fatty acids, as the main fat components has shown the most pronounced manifestations of 
obesity and insulin resistance when compared to coconut fat and fish oil (Buettner et al, 
2006).  These results suggest that the accepted hypothesis that all saturated fatty acids 
exacerbates insulin resistance, needs further study (Buettner et al, 2006).  In the short term (a 
three to four week intervention), high polyunsaturated diet feeding induced insulin resistance 
without hyperglycemia in Wistar rats (Chalkley et al, 2002).  Similarly, Wistar rats fed a 
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safflower oil-based high-fat diet (59% calories as fat) from two months old for a ten months 
period, developed insulin resistance but not diabetes (Chalkley et al, 2002).  It suggested that 
without a genetic predisposition, the high-fat feeding alone does not result in T2D (Chalkley et 
al, 2002).  A study by Krygsman et al showed that not only the percentage dietary fat that 
plays a role in glucose intolerance and insulin resistance but a relationship between fatty acid 
composition and dietary fat (Krygsman et al, 2010). 
 
High-fructose corn syrup (HFCS), as sweetener, is commonly used in food especially 
beverages, including carbonated sodas (Hofmann and Tschöp, 2009).  The use of HFCS has 
been proposed as an important dietary factor that has contributed to the widespread increase 
in human obesity observed in Westernized societies (Hofmann and Tschöp, 2009).  HFCS 
contains 5% more fructose compared to sucrose (“normal sugar”).  Fructose exerts an 
increased perception of sweetness therefore it is preferred by food and soft drink 
manufacturers (Hofmann and Tschöp, 2009). 
 
The addition of fructose to a high-fat diet is commonly used to induce an animal model of T2D 
(Huang et al, 2004).   A study done by Huang et al concluded that a high-fructose diet causes 
hyperinsulinemia, while a high-fat diet results in impaired pancreatic function of insulin 
secretion and glucose intolerance this suggest that high-fructose diet and high-fat diet exerts 
divergent effects on glucose metabolism in rats (Huang et al, 2004).    Relevant differences in 
metabolism of rats fed fructose-enriched diets showed substantial insulin resistance and 
hyperinsulinemia in both lean and obese rats, whereas rats fed a glucose-enriched diet led to 
enhanced insulin sensitivity (Suga et al, 2000).  The metabolism of these sugars where 
comprehensively compared in overweight/obese humans and found that visceral adipose 
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volume was significantly increased in subjects consuming fructose (Stanhope and Havel, 
2009) when compared to glucose consumption (Stanhope et al, 2009).  Fasting plasma 
glucose and insulin concentrations increased and insulin sensitivity decreased in subjects 
consuming fructose but not those consuming glucose (Stanhope et al, 2009).  High-fructose 
diets induce dyslipidemia, decrease insulin sensitivity and increase visceral adiposity 
(Stanhope et al, 2009).   
  
1.8 Diabetes  
Diabetes is defined as a chronic disease involving the β-cells in the pancreatic islets.  In 
diabetes, β-cells cannot produce sufficient insulin or the body cannot efficiently utilize the 
insulin that is being produced (Zimmett, 2001; WHO, 2009).  Diabetes is also associated with 
micro-vascular (retinopathy, nephropathy and neuropathy) and macro-vascular (ischemic 
heart disease, stroke and peripheral vascular disease) complications which generally reduces 
quality of life, life expectancy and increases morbidity (Zimmet et al, 2001; Roglic et al, 2006).  
Uncontrolled diabetes is characterized by hyperglycemia that over time is detrimental to many 
body systems (WHO, 2009).  The recent increase in the incidence of diabetes is due to many 
factors including urbanization, diet, obesity and a sedentary lifestyle (Zimmett et al, 2001; 
Wild et al, 2004).   
 
According to the WHO more than 220 million people worldwide have diabetes and an 
estimated 1.1 million people died from diabetes in 2005.  Projections indicate that deaths 
attributed to diabetes will double from 2005 to 2030 (WHO, 2009).   
The two main forms of diabetes are type 1 diabetes and T2D.   Type 1 diabetes is an auto-
immune disease that is characterized by destruction of pancreatic β-cells and leads to 
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deficient insulin secretion.  Type 1 diabetes patients require exogenous insulin administration 
to control hyperglycemia (Zimmett et al, 2001; WHO, 2009).  Type 2 diabetes is associated 
with obesity and sedentary lifestyle and accounts for 90% of people with diabetes (Zimmett et 
al, 2001; WHO, 2009).  According to a review by DeFronzo, 2004, the pathophysiology of 
T2D starts with normal glucose tolerance, insulin resistance, compensatory hyperinsulinemia, 
with a progression to impaired glucose intolerance and T2D.  The primary defects responsible 
for the progression to T2D is impaired insulin secretion by the β-cells, increased glucose 
production by the liver  and decreased utilization of glucose by peripheral tissue such as 
muscle (DeFronzo, 2010).  These phenomenons have been observed in many diverse 
populations and in animal models such as the rhesus monkey, which closely resembles T2D 
in humans (DeFronzo, 2004).  Such studies have revealed a strong association between 
obesity and the development of T2D (Freemantle et al, 2008).  A decrease in tissue insulin 
sensitivity with a compensatory increase in fasting and glucose-stimulated plasma 
concentrations is the earliest detectable abnormality that exists before the onset of diabetes 
(DeFronzo, 2004).  When the rate of insulin secretion cannot be maintained any longer due to 
β-cell failure and loss of  β-cell mass, fasting hyperglycemia and glucose intolerance follows 
which leads to the progression to T2D (DeFronzo, 2004).   
 
During ingestion of a mixed meal, approximately 50% of glucose is used by the brain, 25% in 
splanchnic area (liver and gastrointestinal tissues) and the remaining 25% in muscle and to a 
lesser extent in adipose tissue (DeFronzo, 2004).  During ingestion of glucose there is an 
increase in plasma glucose concentrations which then in turn stimulates the release of insulin 
by the pancreatic islets to dispose of excess glucose (DeFronzo, 2004).  This causes a 
temporary state of hyperinsulinemia and hyperglycemia which stimulates glucose uptake by 
the splanchnic and muscle tissues (DeFronzo, 2004).  A small amount (approximately 4-5%) 
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of glucose is metabolized by adipocytes, although it plays a major part in maintenance of total 
body glucose disposal by the regulation of FFA from stored triglycerides (DeFronzo, 2004).  
Increased insulin concentrations inhibit lipolysis and cause a decline in plasma FFA 
concentration, resulting in an increase in muscle glucose uptake.  Insulin also suppresses 
glucose production in the liver (DeFronzo, 2004).   
 
1.9 Glucose sensing and insulin secretion 
Glucose transporter 2 (GLUT2) is a facilitative transporter of glucose, fructose and other 
dietary sugars, allowing bidirectional glucose flux and serves as an equilibrator of intra- and 
extra-cellular glucose concentrations, essential to the maintenance of glucose homeostasis 
(Leturque et al, 2005; Leturque et al, 2009).  GLUT2 is located in the plasma membrane of 
liver, pancreas, kidneys, intestines and brain (Thorens et al, 2000; Leturque et al, 2005; 
Leturque et al, 2009).  GLUT2 is able to process high concentrations of sugars mainly due to 
its low-affinity and high-capacity allowing fast equilibration of glucose (Kellett and Brot-
Laroche, 2005; Leturque et al, 2005; Kramer et al, 2009; Leturque et al, 2009).  In the rat it is 
also the main bidirectional glucose transporter in the liver (Leturque et al, 2005).  In the 
presence of high glucose and insulin concentrations, the liver stores glucose as glycogen or 
metabolizes it to lipids.  In the fasted state, glucagon stimulates glycogen degradation 
(glycogenolysis) where glycogen is converted to glucose-6-phosphate which is then 
hydrolyzed to glucose.  Glucose is then exported from the cell via GLUT2 (Leturque et al, 
2005).  Transport of glucose via GLUT2 is the initial event of glucose-induced insulin 
secretion by the pancreatic β-cells and plays a key role in glucose sensing (Leturque et al, 
2005; Cerf, 2007).  The intra-cellular glucose is metabolized by glycolysis in the mitochondria 
in the β-cells.  This triggers the distal step of insulin secretion where adenosine triphosphate  
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(ATP) to adenosine diphosphate (ADP) ratio controls the ATP-dependant-potassium (K+) 
channel closure, causing membrane depolarization and opening of the voltage-dependent 
calcium (Ca2+) channels.  This increases intra-cellular Ca2+ and facilitates the release of 
secretory granules of insulin (Leturque et al, 2005; Cerf, 2007; Leturque et al, 2009).  The 
secretion of insulin thereby stimulates the uptake of glucose in liver, skeletal and adipose 
tissue (Cerf, 2007).   
 
Human studies have revealed that mutations in the GLUT2 gene causes Fanconi-Bickel 
syndrome which is an autosomal recessive disorder of carbohydrate metabolism (Santer et al, 
1998; Bouché et al, 2004; Leturque et al, 2005).  Patients with this disorder suffer from 
hepatomegaly, nephropathy, fasting hypoglycemia, glucose intolerance and growth 
retardation (Santer et al, 1998; Bouché et al, 2004; Leturque et al, 2005).  They are unable to 
tolerate simple sugars in their diets (Santer et al, 1998; Bouché et al, 2004; Leturque et al, 
2005). 
 
Studies in GLUT2-null mice, unable to survive past the first three weeks of life (Thorens et al, 
2000), can be maintained alive by insulin injections (Leturque et al, 2005).  Suggesting that in 
mice no alternative pathway can restore glucose entry and insulin secretion (Leturque et al, 
2005).  These mice present with glucosuria indicating GLUT2 is essential in renal glucose 
reabsorption (Thorens et al, 2000; Leturque et al, 2005).  GLUT2-null mice are 
hyperglucagonemic (Thorens et al, 2000) having a 40% larger liver than their controls due to 
accumulation of excess glycogen (Leturque et al, 2005).   
 
Importantly, in humans a lack of GLUT2 in the pancreatic islets does not alter insulin 
secretion, as in mice (Leturque et al, 2005).  Humans have a fourfold lower level of GLUT2 
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than mice pancreatic β-cells (Leturque et al, 2005) as the major transporter of glucose is 
glucose transporter one (GLUT1) (Zuniga et al, 2001).  Glucose sensing plays a crucial role in 
pancreatic β-cells and impairment of glucose sensing contributes to β-cells dysfunction in rats 
(Cerf, 2007).  A defect in GLUT2 sensing, leads to the inability of the pancreatic β-cells to 
sense changes in glucose can therefore be directly linked to the development of T2D in mice 
(Thorens, 2001).   
 
1.10 Aim of the study 
 To establish the effect of a high-fat and sucrose/fructose feeding on the glucose 
metabolism. 
 The development of insulin resistance and β-cell mass dynamics and β-cell function in 
response to the dietary insult.   
 To assess β-cell glucose transport by the expression of GLUT2. 
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MATERIALS AND METHODS 
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2.1 Animal model and housing 
Wistar rats were used and bred at the Medical Research Council (MRC), Primate Unit, 
Tygerberg, South Africa.  Rats were cared for and managed according to documented 
standard operating procedures (SOP) of the Primate Unit (De Villiers, 2007) and in 
accordance with the MRC Guidelines for the Use of Animals in Research and Training and 
the National Code for Animal Use in Research.  Ethical approval for this study was obtained 
from the ethics committee at the Medical Research Council of South Africa (ECRA # 10/09).  
After weaning, male Wistar rats (three week old) were placed and maintained on three 
different experimental diets for either three or twelve months.  Rats were individually caged on 
sterilized absorbent corn cob bedding (Cobtech, Harrismith, SA) to ensure comfort.  Clean 
cages and bedding were provided weekly. The rats had access to clean drinking water at all 
times. The rats were maintained in a temperature controlled room of 24 – 26 °C, humidity of 
45 – 55%, 15 -20 air changes per hour and on a 12 hour light/dark cycle.  
 
2.2 Experimental diet composition and calorific content 
Three experimental diets varying in fat and carbohydrate content were designed for the study.   
The diets were designed to maintain similar protein content of approximately 15% only 
varying fat and carbohydrate content.  The reason being that protein deficiency can lead to 
defects in insulin signaling (Araujo et al, 2004).  The standard rat chow consisted of dry 
pellets and the high-fat diet, produced by the Primate Unit, consisted of a moist patty.   
The macro-nutrient and calorific content is listed in Table 1. 
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Table 1: Dietary composition of the diets 
 
 
2.3 Experimental design 
At three weeks of age, weanling male Wistar rats were randomized into two experimental 
study periods of three groups each (n= 60): 
2.3.1 Study 1 (Three months diet groups): 
Control diet group received standard maintenance rat chow (Atlas Animal Feed, Cape Town) 
and water ad libitum (n= 10).  High-fat diet (HFD) fed group received HFD and water ad 
libitum (n= 10).  Café diet (CFD) fed group received the HFD and 15% sucrose/fructose in 
drinking water ad libitum (n= 10).  Diets were administered for three months. 
2.3.2 Study 2 (Twelve months diet groups): 
Control diet group received standard maintenance rat chow (Atlas Animal Feed, Cape Town) 
and water ad libitum (n= 10).  HFD fed group received HFD and water ad libitum (n= 10).  
CFD fed group received HFD and 15% sucrose/fructose in drinking water ad libitum (n= 10).  
Diets were administered for twelve months. 
Control HFD CFD
Protein 15.13 15.09 15.09
Fat 10.69 40.17 40.17
Saturated (SFA) 3.98 18.27 18.27
Monounsaturated (MUFA) 2.92 11.45 11.45
Polyunsaturated (PUFA) 2.24 5.75 5.75
Carbohydrate 74.16 44.73 44.73
2.60 2.06 2.06
n/a n/a 0.60
2.60 2.06 2.66
Kcal/g of food
Kcal/g of sucrose/fructose 
Total Kcal/g  of diet
%
 E
n
e
rg
y
 
0.00 15.000.00
Nutrients
Refined sugar:(99.98% carbohydrate) 
7.5% sucrose: 7.5%   fructose
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2.4 Food intake 
Food intakes were measured during the last month before termination and expressed as 
amount of calories consumed. Calories of 15% sucrose/fructose solution: (15/100) x 4 kcal/g)) 
= 0.6 kcal/g of energy (Stanfield and Hui, 2009).  
 
2.5 Body weights and retroperitoneal fat (RF) weights 
Body weights were recorded at termination of the studies.  RF pads (Fig 5) were excised from 
the rats and weighed as a measurement of adiposity and to estimate the degree of obesity.   
 
Figure 5: Photograph presentation of left RF pad with the left kidney (LK) attached   
 
RF 
LK 
1cm 
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2.6 Intravenous Glucose Tolerance Test (IVGTT) and glucose stimulated insulin 
secretion rate (GS-ISR) combined with radioactive labeled glucose  
Baseline blood samples were collected from tip of the tail prior to intravenous glucose 
administration. For the IVGTT and GS-ISR five rats from each group were anaesthetized by 
inhalation of 98% oxygen and 2% fluothane (AstraZeneca Pharmaceuticals).  Once 
anaesthetized, a cannula (26 gauge, Neotec Medical Industries, Singapore) was inserted into 
the tail vein and 500 microliters (µl) prewarmed radioactive labeled 2-deoxy-[3H]-D-glucose 
(53Ci/mmol specific activity, Amersham Bioscience) solution at a dose of 1µCi/500g in 1 
milliliter (ml) sterile saline was injected intravenously over 1 minute (min) to determine 
intramuscular, liver and fat glucose uptake.  Followed by 500 mg/kg of 50% prewarmed 
(35°C) dextrose (Dextrose-Fresenius 50%, PE, SA) for the measurement of intravenous 
glucose tolerance and glucose stimulated insulin secretion.  Following administration of 2-
deoxy-[3H]-D-glucose and dextrose, plasma glucose concentrations were measured after 1, 2, 
3, 5, 10, 20, 30, 40, 50 and 60 min.  Five hundred µl blood samples, for insulin determination 
(refer to section 2.8), were collected at 5, 10, 30 and 60 min and samples stored in -20°C until 
analyzed.  After one hour the rats were euthanized with 50 mg/kg sodium pentobarbital 
euthanase (Bayer Pty.Ltd., Animal Health Division, Isando, SA) via intraperitoneal injection.  
Abdominal fat, skeletal muscle and liver tissue was harvested in cryotubes and snap frozen in 
liquid nitrogen.  Samples were stored in -80°C until analyzed as described in section 2.15. 
 
2.7 Blood collection and organ harvesting 
After three and twelve months on their respective diets, the remaining five rats per group were 
starved for three hours before blood collection and sacrifice.  Fasting blood glucose 
concentrations were measured from the tail tip using a glucometer (Asencia, Bayer 
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Healthcare, Mishwaka, USA).  Rats were anesthetized by sodium pentobarbital intra-
peritoneal injection and blood was collected in Vacutainer® SST™ (BD Biosciences, 
Woodmead, SA) gel tubes from the abdominal vena cava.  After collection, blood was 
centrifuged at 4000 rpm for 15 min at 4°C and serum was removed and stored at -20°C for 
insulin determination (refer to section 2.8).  After blood collection the rats were euthanized by 
exsanguination under anesthesia.  The pancreas, liver, kidney, heart and muscle were 
removed and fixed for histological evaluation in 10% phosphate buffered formalin overnight.  
A sample of pancreas was also placed in 2.5% glutaraldehyde (Merck, Darmstadt, Germany) 
in 0.1M phosphate buffer pH 7.2 for electron microscopy.  Only pancreas sections were used 
in this study.   
 
2.8 Insulin determination 
Serum insulin concentrations were determined by radioimmunoassay (RIA) using a Linco rat 
insulin kit (Linco Research, St. Charles, MO, USA).  Procedure was done over two days.  
On the first day, standards and quality controls were prepared according to manufacturer‟s 
instructions and samples were prepared in duplicate.  Two hundred µl assay buffer was 
added to borosilicate tubes followed by 100 µl of the rat serum samples.   One hundred µl of 
125I-Insulin was then added to samples.  One hundred µl of rat insulin antibody was then 
added to all the samples.  Samples were then vortexed, covered and incubated overnight at 
4°C. 
 
The following day, a volume of 1 ml precipitating reagent was added to all samples.  Samples 
were then vortexed and incubated for 20 min at 4°C.  Samples were centrifuged at 4°C for 30 
min at 4000 x g.  The supernatant were aspirated and the visible pellet remained in tube.  
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Samples were analyzed using a gamma counter (Perkin-Elmer precisely wizard 1470 
automatic gamma counter, Monza, Italy).  Results were expressed in ng/ml.   
 
2.9 Calculation of Homeostatic model assessment of insulin resistance (HOMA-IR) 
(Method adapted from Shinohara et al, 2002) 
HOMA-IR was used to estimate the degree of insulin resistance (Bonora et al, 2002; 
Shinohara et al, 2002).  HOMA-IR was computed using the fasting plasma glucose 
concentrations (fPG) (mmol/l) multiplied by the fasting serum insulin concentrations (fINS) 
(ng/ml) divided by 22.5 ((fPG x fINS) / 22.5).  A low HOMA-IR value indicates high insulin 
sensitivity and a high HOMA-IR indicates low insulin sensitivity (insulin resistance) (Bonora et 
al, 2002). 
 
2.10 Calculation of glucose clearance rate (GCR) 
Glucose clearance rate was calculated using the formula: (0.693 / (t-10)) x 100 as described 
by Kanter et al 1988.   
 
2.11 Calculation of AUC 
Area under the curve values were calculated using the trapezoidal method (Graphpad Prism 
version 5.02, Graphpad). 
 
2.12 Preparation of tissues for histology 
Tissue samples were fixed in buffered formalin (pH 7.4) for 12 hours, labeled with the 
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appropriate histology number and placed in tissue cassettes.  The cassettes were then placed 
in an automated histology tissue processor (Leica TP 1020, Leica Microsystems, Nussloch, 
Germany) and processed overnight according to a set program (Table 2).   
 
Table 2: Processing schedule for tissue 
Carousel position Reagent Time (hours) 
1 10 % formalin 12 hour fixation 
2 70% alcohol 1 
3 80% alcohol 1 
4 95% alcohol 2 
5 95% alcohol 1 
6 100% alcohol 2 
7 100% alcohol 2 
8 Xylene 1 
9 Xylene 1 
10 Xylene 1 
11 Wax 2 
12 Wax 3 
The total running time for a complete cycle was 17 hours.     
2.12.1 Tissue imbedding and sectioning 
The tissue cassettes were removed from the processor and embedded in paraffin wax.  
Sections, ranging between 5 - 7 µm in thickness, were then cut using a rotary microtome 
(Leica RM 2125 RM, Leica Microsystems, Nussloch, Germany) floated onto warm (30°C) 
water to remove wrinkles and placed onto 3-aminopropyltriethoxy-Silane (APES) coated 
slides.   
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2.12.2 Coating of APES slides 
Sections were placed in metal slide staining racks and immersed in acetone for 2 min to 
remove any dirt from the slides.  Sections were air dried for 5 min.  Two % APES solution 
were prepared in acetone (98 ml acetone + 2ml APES).  Sections were immersed in 2% 
APES solution for 2 min.  Sections were washed in acetone by dipping sections 
approximately 10 times and this step was repeated twice.  Sectioned were allowed to dry at 
60°C in an incubator for approximately 30 min. 
 
2.13 Immunohistochemistry (IHC)   
Alpha (α) and β-cells were identified by immunostaining using anti-insulin (monoclonal mouse 
anti-insulin, clone K36aC10, Sigma Immunochemicals, St. Louis, MO, USA) and anti-
glucagon antibodies (polyclonal rabbit anti- glucagon, Dako Cytomation, Carpinteria, CA, 
USA).  Immunohistological staining to demonstrate cell proliferation was performed using MIB 
5 (monoclonal mouse anti-rat Ki-67 antigen, clone MIB5, Dako, Glostrup, Denmark) and 
insulin (Polyclonal guinea pig anti-insulin, Dako, Carpinteria, CA, USA) antibodies.  The effect 
of the diets on glucose transport was assessed by IHC staining of GLUT2 (WAK-Chemie, Bad 
Soden, Germany). 
 
2.13.1. Double immunolabeling for glucagon and insulin in the rat pancreas  
(Method adapted from Cerf et al, 2005). 
Procedure was performed over two days. 
On the first day sections were dewaxed in an oven at 60°C for 30 min, placed in xylene for 
20min, hydrated in 95% ethanol for 4 min and rinsed in water.  The sections were then 
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incubated for 5 min in 3% hydrogen peroxide (H2O2) to block for endogenous peroxidases.  
The sections were rinsed in 50 mM-tri(hydroxymethyl)-aminomethane (Tris) buffered saline 
(TBS) for 5 min in a staining jar on a magnetic stirrer at pH 7.2.  To block non-specific binding 
sections were incubated for 20 min in 1:20 normal goat serum (NGS) (MRC Animal facility, 
Delft, SA).  This prevents the secondary antibody from cross-reacting with endogenous 
immunoglobulins in the tissue and eliminates non-specific fragment crystallizable region (Fc 
region) binding of both the primary and secondary antibody.  After blotting the excess serum, 
a 1:50 dilution of the primary antibody, anti-glucagon, was added, and the sections were 
incubated for 30 min at room temperature.  Thereafter, the sections were jet washed with TBS 
and rinsed in TBS for 5 min.  After rinsing, sections were incubated in a dilution of 1:1000 
biotinylated anti-rabbit IgG (Vector laboratories, Burlingame, CA, USA) for 30 min in a 
moisture chamber.  To remove unbound antibody sections were jet washed and rinsed in TBS 
buffer for 10 min.  A volume of 5 ml of TBS, at pH 7.2, with 1 drop (20 µl) of solution A and 1 
drop (20 µl) of solution B of Vectastain (Vector laboratories, Burlingame, CA, USA) was 
applied to the sections and incubated for 60 min at room temperature.  Sections were then 
washed in TBS buffer for 10 min at pH 7.2.  Immunostaining was visualized using liquid 
diaminobenzidine tetrachloride (DAB) Plus Substrate Chromagen System (Dako Corporation, 
Carpinteria, CA, USA) using 1 drop (20 µl) DAB chromagen per 1 ml of substrate buffer 
provided.  An insoluble brown reaction DAB precipitate developed at the glucagon 
antibody/antigen binding site.  Before applying the second primary antibody, sections were 
washed and rinsed with distilled water for 5 min.  After rinsing and drying the slides, 1:20 
normal horse serum (NHS) (MRC Animal facility, Delft, SA) was applied to slides in a 
moisture chamber and incubated for 20 min at room temperature.  Excess serum was blotted 
and a dilution of 1:10000 anti-insulin (Sigma Immunochemicals St. Louis, MO, USA) was 
applied to sections in a moisture chamber and incubated overnight (16 hours) at 4°C.   
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Following overnight incubation, sections were jet washed and rinsed with 0.05M TBS for 5 
min.  One hundred µl of rabbit/mouse link (Envision G/2 System/AP, Rabbit/Mouse Kit, Dako, 
Denmark) were then added to slides and incubated for 30 mins.  After incubation and washing 
in TBS for 10 min, AP Enzyme Enhancer (Envision G/2 System/AP, Rabbit/Mouse Kit, Dako, 
Denmark) was applied to sections and incubated in a moisture chamber for 30 min at room 
temperature.  Sections were washed with 0.5M TBS.  One hundred µl of substrate working 
solution (Envision G/2 System/AP, Rabbit/Mouse Kit) was applied to each section for 3 min.  
An insoluble red reaction of the permanent red precipitate developed at the insulin 
antibody/antigen binding site.  Sections were washed and rinsed with distilled water for 5 min 
before counterstaining with Mayers Haemotoxylin for 2 min.  Sections were then left to “blue” 
in running tap water for 30 min and blotted on paper towel to remove water.  After air drying, 
the sections were mounted with Entellan
®
 (Merck, Darmstadt, Germany) and cover slipped. 
 
To verify the specificity of the immunohistochemistry, three negative method controls were 
included with each batch of sections stained.  To demonstrate non-specific binding of link 
antibodies and endogenous enzyme activity both the primary antibodies (glucagon and 
insulin) were omitted.  A second method control was included where the insulin antibody was 
omitted thereby demonstrating the specificity of glucagon staining.  A third method control 
was included where the glucagon antibody was omitted thereby demonstrating the specificity 
of insulin staining. 
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2.13.2 Immunolabeling for GLUT2  
(Method adapted from Cerf et al, 2006) 
Sections were dewaxed as described at the beginning of section 2.13.1.  The hydrated 
sections were then incubated in 3% H2O2 in distilled water for 5 min to inhibit tissue 
endogenous peroxidases.  After exposing the slides to the H2O2, the sections were washed in 
TBS for 10 min.  To reduce non-specific antibody binding the sections were incubated in 1:20 
diluted NGS for 20 min.  Excess serum was blotted and the primary rabbit anti-rat GLUT2 
(WAK-Chemie, Bad Soden, Germany) antibody diluted 1:300 was applied to the sections for 
30 min.  After incubation the sections were washed in TBS for 5 min and rabbit biotinylated 
antibody was added for 30 min, followed by another 5 min wash in TBS.  The sections were 
then incubated in avidin D-biotinylated horseradish H complex (Vectastain) for 60 min.  
Immunolabeling was revealed by incubating the sections for 5 min in liquid DAB Plus 
Substrate Chromagen System (Dako Corporation, Carpinteria, CA, USA). GLUT2 
antibody/antigen binding was visualized by the brown DAB precipitate.  The sections were 
counterstained with haematoxylin for 2 min, mounted with Entellan
®
 and cover slipped.   
 
To verify the specificity of GLUT2 staining method controls were included, where the primary 
antibody (GLUT2) was omitted.   
 
2.13.3 Double immunolabelling for MIB5 and insulin in the rat pancreas 
Sections were labeled over two days. 
Sections were dewaxed as described at the beginning of section 2.13.1.  The sections were 
then incubated in 3% H2O2 in distilled water for 5 min to inhibit tissue endogenous 
peroxidases.  Antigen retrieval was performed in 0.01 M citrate buffer pH 6.0 at 125°C for 30 
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seconds and 90°C for 10 seconds using a Pascal pressure cooker (Dako Cytomation, CA, 
USA).  Sections were then removed from Pascal and allowed to cool for 20 min.  Sections 
were rinsed with TBS for 5 min.  After rinsing and drying the slides, 1:20 NHS was applied to 
slides in a moisture chamber and incubated for 20 min at room temperature.  After blotting the 
excess serum, a 1:50 dilution of the primary antibody, anti-MIB5, was added, and the sections 
were incubated in moisture chamber overnight (16 hours) at 4°C. 
 
After overnight incubation insulin labeling was performed as described previously for insulin 
and glucagon double-immuno labeling (Section 2.13.1 Day 2).  The difference being the 
insulin antibody used was a polyclonal guinea pig anti-insulin (Dako, Carpinteria, CA, USA).   
 
To verify the specificity of the IHC staining, three negative method controls were included with 
each batch of sections stained.  To demonstrate non-specific binding of the relevant link 
antibodies and endogenous enzyme activity both the primary antibodies (MIB5 and insulin) 
were omitted.  A second method control was included where the MIB5 antibody was omitted 
thereby confirming the specificity of the link antibody binding and enzymatic detection of 
insulin.  A third method control was included where the insulin antibody was omitted thereby 
demonstrating the specificity of the MIB5 immunostaining.  Positive MIB5 controls were 
included using gastrointestinal tract sections as the mucosa have high rates of proliferation. 
 
2.14 Electron microscopy imaging and staining 
(Method: Diagnostic Electron Microscopy Unit, Anatomical Pathology, NHLS, Tygerberg 
Hospital, Tygerberg) 
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2.14.1 Tissue preparation 
Pancreas tissue was fixed in 2.5% glutaraldehyde (Merck, Darmstadt, Germany) in 0.1M 
phosphate buffer pH 7.2 at 4°C for overnight for 16 hours.  The fixed pancreas tissue was cut 
into 1mm blocks for processing.  After a 5 min wash in phosphate buffer the tissue was fixed 
in 3% osmium tetroxide (Merck, Darmstadt, Germany) in Palade‟s buffer (2.89 g sodium 
barbitol (Merck, Darmstadt, Germany) and 1.15 g sodium acetate (Merck, Darmstadt, 
Germany) in 100 ml distilled water) for 1 hour.  After the secondary fixation in osmium 
tetroxide the tissue was washed in distilled water and transferred into processing baskets and 
processed with a Leica EM Tissue Processor (Leica Microsystems, Nussloch, Germany) 
according to an established protocol (Table 3).   
Table 3: Tissue processing schedule for electron microscopy 
Carousel position Reagent Time (min) 
1 10% uranyl acetate 15 
2 70% alcohol 10 
3 70% alcohol 10 
4 10% uranyl nitrate 20 
5 100% alcohol 15 
6 100% alcohol 20 
7 100% alcohol 30 
8 100% alcohol : Spurr‟s resin 90 
9 Spurr‟s resin 60 
10 Spurr‟s resin 60 
11 gelatine capsule 2 
Tissue sections were then embedded in Spurr‟s resin (TAAB Laboratories Equipment Ltd., 
UK) into gelatine capsules (Eli Lilly, SA) overnight at 60°C.  Blocks were allowed to cool and 
carefully marked. 
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2.14.2 Tissue sectioning and staining 
A Leica EM UC7 (Leica Microsystems, Nussloch, Germany) ultratome was used to cut ultra 
thin (100 nm) sections from the resin blocks.  Glass knives were made using a knifemaker 
(LKB 7800, Biostad, Canada) and glass strips (LKB, Biostad, Canada).  A water trough was 
attached to each knife by using autoclave tape and melted dental wax.  Ultra thin sections 
were collected from the water surface onto 200G mesh copper wire grids (Wirsam Scientific, 
SA) allowed to dry on filter paper before staining.  To enhance contrast, the grids were firstly 
stained with 2% uranyl acetate (Agar Scientific Ltd., SA) in 70% alcohol for 10 min.  
Thereafter the sections were rinsed in 70% alcohol and distilled water.  To further increase 
cell membrane contrast, the grids were stained with Reynold‟s lead acetate (2.66g lead nitrate 
(Merck, Darmstadt, Germany) and 3.52 g sodium citrate (Merck, Darmstadt, Germany) in 60 
ml distilled water) for 5 min.  Finally the grids were washed in distilled water, allowed to dry on 
filter paper and then scoped with a JOEL GEM 1011 (JOEL Ltd, Japan) transmission electron 
microscope. 
 
2.15 Assays of 2-deoxy-[3H]-D-glucose uptake- muscle, liver and fat tissue  
(Method adapted by Chadwick et al, 2007) 
Tissues collected (as described in section 2.7) were weighed and placed in Eppendorf tubes.  
An equal volume of 30% potassium hydroxide (KOH) in µl‟s, per tissue weight (i.e. 242 mg 
tissue + 242 µl 30% KOH) was added to the tissue in the Eppendorf tube and the tube placed 
in a boiling beaker of water for 5-30 min until dissolution of the tissue. Once dissolved, 
samples were removed from the beaker, thoroughly mixed and transferred to glass vials.  In 
liver and fat tissue 100 µl of 30% H2O2 was added to bleach samples. After the initial reaction 
(after foaming ceases), and to complete discoloration, a second addition of 100 µl 30% H2O2 
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was added.  Eight ml liquid scintillation cocktail (Ultima Gold, Perkin Elmer, CT, USA) was 
added to the vials and allowed to equilibrate overnight for 16 hours then counted in a  
scintillation counter (2200CA Tri-carb Series, Packard Instrument Company, IL, USA).   
Data were expressed as counts per minute (cpm) and disintegrations per minute (dpm) 
values.  Results were analyzed using the dpm value per gram of tissue sample (Chadwick et 
al, 2007; Verhelst et al, 1998).  Each sample was read for 10 min.  All samples were done in 
triplicate.  Sample readings were normalized according to a standard curve for tritium [3H] that 
is installed in the 2200CA Tri-carb Series liquid scintillation counter when calibrated. 
 
2.16 Image analysis of immuno-labeling for glucagon and insulin 
2.16.1 Image capture 
Stained sections of pancreata were captured using the x10 objective attached to an Olympus 
BX60 light microscope equipped with a digital camera (Leica DC290, Wetzlar, Germany) and 
interfaced with Leica Qwin Professional software (Leica, Wetzlar, Germany).  Every alternate 
field was scanned and saved as a tiff image with a resolution of 768 x 1024 pixels.  Five 
slides per group were evaluated.  
 
2.16.2 Calibration 
The software was calibrated for the x10 objective using the inner squares of Neubauer cell 
chamber, which has a known area of 2500 µm2.  The square areas were determined by red, 
green, blue (RGB) colour segmentation of 1, 2, 3, 4, 8, 12 and 16 squares.  The determined 
areas were plotted against the actual known measurements using a line graph.  The slope of 
the line was checked for linearity. 
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2.16.3 Using the correct calibration 
In order to use the correct calibration for a specific objective lens, the correct lens was 
selected in the Qwin select lens feature and the update feature was selected in the system 
calibration feature.  
 
2.16.4 Image analysis 
For the determination of tissue areas, each image was subjected to RGB colour segmentation 
so that the whole section surface was selected and converted to a binary image.  The area of 
the binary image was determined and the data automatically transferred to Microsoft Excel.  
To determine islet areas, images containing islets were subjected to RGB colour 
discrimination to select both the insulin positive (red) and glucagon positive (brown) cells.  
The resultant binary image was subjected to a closing function for 30 cycles and converted to 
a new binary image representing the whole islet, including areas not stained positively for 
glucagon and insulin.  The area was then determined and automatically transferred to 
Microsoft Excel.  The α-cell area was determined by subjecting the image to RGB 
segmentation to obtain a binary image from the glucagon positive cells (brown).  The area of 
the binary image was determined and automatically transferred to Microsoft excel.  The β-cell 
area was determined as for α-cell area, except that a binary image was obtained to represent 
the area of insulin positive cells (red).   
 
2.16.5 Morphometrical parameters 
2.16.5.1 Ratio of endocrine tissue to total tissue area 
To determine ratio of endocrine to total tissue area, the total islet area was divided by the total 
tissue area. 
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2.16.5.2 Ratio of β-cell to α-cell area 
β-cell area to α-cell area was determined by dividing the total β-cell area by the total α-cell 
area. 
2.16.5.3 Islets per unit area 
The total number of islets counted was divided by the total tissue area expressed in cm2 to 
determine the number of islets per cm2 of pancreas tissue. 
2.16.5.4 The distribution of different sizes of islets to the total number and total area of 
islets 
The total number of islets were counted and classified according to size as follows: 1-2500 
µm2; 2501-7500 µm2; 7501-12500 µm2; 12501-20000 µm2 and >20001 µm2.  To determine 
the percentage contribution of the number of islets in each classification of islet size, the 
number of islets in each group was expressed as a percentage of the total number of islets 
counted.  To determine the percentage contribution of the area of islets in each classification 
of islet size, the total area of islets in each group was expressed as percentage of the total 
area of islets measured. 
 
2.17 GLUT2 immunohistochemical evaluation 
Pancreatic sections stained for GLUT2 were evaluated using a light microscope at a 
magnification of x 100.  GLUT2 positivity was assessed using an adapted scoring method as 
described by Kramer et al, 2009.  The scoring method was based on the number of GLUT2 
positive cells within pancreatic islets (Table 4).  All sections were independently evaluated by 
two experienced individuals who were blinded.  Five slides per group were evaluated.  
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Table 4: Evaluation of GLUT2 positivity 
 
 
 
2.18 MIB5 and insulin immunohistochemical evaluation 
Pancreatic sections double labeled for MIB5 and insulin were assessed using a light 
microscope at a magnification of x 100. Positivity was assessed using an adapted scoring 
method as described by Jorda et al 2003 (Table 5).  All sections were independently 
evaluated by two experienced individuals were blinded.  Five slides per group were 
evaluated. 
 
Table 5: Evaluation of MIB5 positivity 
 
 
2.19 Statistical analysis 
Data generated were entered into Microsoft Excel and analyzed by calculating the means and 
standard deviation. Statistical significance was calculated with Student‟s t-test or one-way 
ANOVA (with Dunnett‟s post-hoc test if p<0.05).  A p-value of p≤0.05 was deemed to be 
statistically significant.  
 
0   no visible staining in islets
1   few/scattered positive staining cells in islets
2   moderate staining of most cells in islets
3   strong staining of most cells in islets
GLUT2 Scoring
0 no positivity
1 < 5% of β-cells staining positively
2 5% -25% of β-cells staining positively
3 >25% of β-cells staining positively
MIB5 Scoring
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CHAPTER THREE 
RESULTS 
  
39 
 
3.1 Food intake 
The rats were maintained on laboratory chow diets for three weeks where after they were 
randomly allocated to the three different diets and maintained for either three or twelve 
months.  The average daily calorific intake at three months of the HFD and CFD fed rats was 
significantly higher than the calories consumed by the control diet rats (99.94 ± 20.29 and 
99.44 ± 9.21 vs. 70.53 ± 7.58 kcal/day respectively; p<0.0001) (Table 6 and Fig 6). 
Calorific intake at twelve months of the HFD and CFD was significantly increased compared 
to the control (125.66 ± 13.95; p<0.0001 and 104.69 ± 17.42; p=0.001 vs. 92.56 ± 9.00 
kcal/day respectively).  Of interest was that the calorific intake of the rats fed a HFD was 
significantly increased compared to the CFD at twelve months (p =0.02) (Table 6 and Fig 7). 
 
Table 6: Food and calorific intakes of different diets at three and twelve months 
 
 
 
 
 
 
Food intake:    
  g/day
Ave kcal/g     
per day
35.60 ± 3.46 92.56 ± 9.00
61.00 ± 6.77 125.66 ± 13.95
33.97 ± 9.68 104.69 ± 17.42
27.13 ± 2.92 70.53 ± 7.58
48.51 ± 9.85 99.94 ± 20.29
35.51 ± 5.22 99.44 ± 9.21CFD
3 months
12 months
Control
HFD
CFD
Control
HFD
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Figure 6: Calorific intake at three months  
Calorie intake was calculated from food and liquid intake.  Values are expressed as mean ± 
SD.  CFD and HFD vs. control, *** p < 0.0001. 
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Figure 7: Calorific intake at twelve months  
Calorie intake was calculated from food and liquid intake.  Values are expressed as mean ± 
SD.  CFD vs. control, ** p= 0.001; HFD vs. control, *** p< 0.0001 and HFD vs. CFD, † p= 
0.02. 
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3.2 Body weight and retroperitoneal fat 
Results shows average body weight and RF pad weight at termination of studies at three and 
twelve months.  After three months feeding, the body mass of the rats maintained on the HFD 
and CFD were significantly higher compared to controls (470.90 ± 45.19 g; p=0.0147 and 
528.20 ± 48.32 g; p=0.0008 vs. 394.80 ± 31.19 g) (Table 7 and Fig 8).   
The RF pad weight at three months of the HFD and CFD fed rats was significantly higher than 
that of the control diet rats (12.35 ± 2.53 g; p=0.0001 and 18.41 ± 6.97 g; p=0.0012 vs. 3.02 ± 
1.00 g) (Table 7). 
After twelve months the body mass of the HFD and the CFD fed rats were significantly higher 
than the controls (908.61 ± 131.14 g and 947.20 ± 51.46 g vs. 599.07 ± 35.69 g; p<0.0001) 
(Table 7 and Fig 9).  There were no significant differences in body weights between the rats 
fed a HFD and CFD at both three and twelve months. 
The RF pad weight at twelve months of the HFD and CFD fed rats was significantly higher 
than that of the controls (52.72 ± 16.97 g and 56.20 ± 9.19 g vs. 10.81 ± 3.39 g; p<0.0001) 
(Table 7).  There were no significant differences between the RF pads of rats fed a HFD and 
CFD at both three and twelve months. 
A photograph of the HFD and control fed rat at twelve months shows the somatic changes in 
fat deposits between the rats fed different diets (Fig 10) and also excess fat accumulation in a 
rat fed HFD for twelve months (Fig 11). 
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Table 7: Comparison between body weight and RF weights at three and twelve months 
 
 
Values are expressed as mean ± SD.  Body weights at 3 months: CFD vs. control, *** 
p=0.0008; HFD vs. control, * p=0.0147 and 12 months: CFD and HFD vs. control, *** 
p<0.0001. RF weight at 3 months: CFD vs. control, ** p=0.0012; HFD vs. control, *** 
p=0.0001 and 12 months: CFD and HFD vs. control, *** p< 0.0001. 
 
 
 
 
 
 
 
 
CFD
12 months
Control
HFD
CFD 947.20 ± 51.46*** 56.20 ± 9.19***
394.80 ± 31.19 3.04 ± 1.00
470.90 ± 45.19* 12.35 ± 2.53***
528.20 ± 48.32*** 18.41 ± 6.97**
Body weight (g) RF weight (g)
599.07 ± 35.69 10.81 ± 3.39
908.61 ± 131.14*** 52.72 ± 16.97***
3 months
Control
HFD
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Figure 8: Body weight at three months  
Values are expressed as mean ± SD.  CFD vs. control, *** p=0.0008; HFD vs. control, * 
p=0.0147.   
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Figure 9: Body weight at twelve months  
Values are expressed as mean ± SD.  CFD and HFD vs. control, *** p<0.0001. 
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Figure 10: Photograph of Wistar rats at twelve months fed HFD and control diets 
 
 
 
Figure 11: Photograph of Wistar rat on HFD at twelve months showing abdominal (AF) 
and subcutaneous fat (SF) deposition 
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3.3 Fasting plasma glucose and serum insulin concentrations    
At three months there were no significant differences in fasting glucose concentrations 
between the three groups (control; 5.8 ± 10.4 mmol/l vs. HFD; 5.1 ± 11.1 mmol/l vs. CFD; 6.1 
± 0.2 mmol/l) (Fig 12). Fasting insulin concentrations showed significant increase in the CFD 
fed rats when compared to the control rats (15.3 ± 5.2 ng/ml vs. 6.3 ± 1.9 ng/ml; p=0.01) (Fig 
12). 
 
At twelve months fasting blood glucose concentrations were significantly increased in the 
CFD group compared to the control and HFD fed group (7.1 ± 1.5 mmol/l vs. 5.7 ± 0.8 mmol/l; 
p=0.006 and 6.1 ± 1.1 mmol/l; p=0.03 respectively) (Fig 13).  In addition, fasting insulin 
concentrations were significantly decreased in the HFD group vs. the control and CFD fed 
groups (4.5 ± 2.9 ng/ml vs. 8.5 ± 5.3 ng/ml; p=0.01 and 11.6 ± 6.1 ng/ml; p=0.0003 
respectively) (Fig 13). 
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Figure 12: Fasting plasma glucose and insulin concentrations at three months 
Values are expressed as mean ± SD.  Glucose: p>0.05 in all groups compared to control.  
Insulin: CFD vs. control, * p=0.01. 
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Figure 13: Fasting plasma glucose and insulin concentrations at twelve months 
Values are expressed as mean ± SD.  Glucose: CFD vs. controls, ** p=0.006; vs. HFD, † 
p=0.03.  Insulin: HFD vs. control, * p=0.01; vs. CFD, ††† p= 0.0003.   
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3.4 HOMA-IR calculation of insulin resistance  
The assessment of HOMA-IR as a degree of insulin resistance was measured using a 
standard formula, ((fPG x fINS) / 22.5).  At three months insulin resistance as defined by 
HOMA-IR was significantly increased in the CFD vs. controls (4.14 ± 1.46 vs. 1.64 ± 0.55; p= 
0.01) (Table 8).  At 12 months HOMA-IR was significantly increased in the CFD group vs. the 
controls and the HFD group (3.69 ± 2.01 vs. 2.10 ± 1.31; p=0.03 and 1.28 ± 1.11; p=0.0003) 
(Table 8). 
 
Table 8: Fasting glucose (fPG), insulin concentrations (fINS) and HOMA-IR values at 
three and twelve months  
 
Values are expressed as mean ± SD.  HOMA-IR at 3 months: CFD vs. controls, * p=0.01. At 
12 months CFD vs. controls, * p=0.03; vs. HFD, ††† p= 0.0003.   
 
 fPG (mmol/l)  fINS (ng/ml)  HOMA-IR
6.05 ± 1.07 4.45 ± 2.96* 1.28 ± 1.11
7.14 ± 1.54**† 11.61 ± 6.07††† 3.69 ± 2.01*†
6.08 ± 0.20 15.27 ± 5.17* 4.14 ± 1.46*
5.67 ± 0.78 8.52 ± 5.38 2.10 ± 1.31
5.84 ± 0.43 6.28 ± 1.86 1.64 ± 0.55
5.08 ± 1.08 8.16 ± 4.56 2.03 ± 1.19
12 months
Control
HFD
CFD
Control
HFD
CFD
 Parameters
3 months
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3.5 Intravenous glucose tolerance test (IVGTT) and glucose stimulated-insulin 
secretion rate (GS-ISR) 
There were no significant differences at all IVGTT time points at three months of the 
respective diets (Fig 14a).  The AUC values also showed no difference between between 
groups at three months (Fig 14b).  However, compared to the controls the glucose clearance 
rate of the HFD and CFD fed rats was diminished (3.32 ± 2.72 vs. 1.15 ± 1.10; p =0.1367 and 
1.78 ± 1.07; p = 0.2739) at three months although this was not significant (Table 9).   After 3 
months the GS-ISR of the CFD fed group showed increased peak insulin values at 5 (6.49 ± 
3.49 ng/ml) and 10 min (3.95 ± 3.34ng/ml) after glucose stimulation compared to HFD (5 min: 
4.74 ±  4.69 and 10 min: 2.09 ± 2.92 ng/ml) and control (5 min: 3.58 ±  2.28 and 10 min: 1.99 
± 1.80 ng/ml) (Fig 15a).  The AUC value of the GS-ISR (control: 68.60 ± 45.96; HFD: 104.80 
± 122.80; CFD: 142.20 ± 104.04; p<0.05) was also increased, albeit not significant (Fig 15b).   
 
At twelve months, the IVGTT of the CFD showed increased peak values at 3 min (22.70 ± 
6.28 mmol/L) compared to HFD (15.73 ± 3.23 mmol/L; p= 0.04) (Fig 16a).  Glucose 
concentrations at  5 min (23.26 ± 2.12 mmol/L) and 10 min (19.90 ± 2.03 mmol/L) of the 
IVGTT were significantly increased when compared to both HFD (5 min: 15.57 ± 1.15; 
p<0.0001 and 10min: 13.60 ± 1.44 mmol/L; p= 0.0002) and controls (5 min: 14.20 ± 4.83; p= 
0.003 and 10 min: 14.46 ± 4.59 mmol/L; p= 0.03) (Fig 16a).  IVGTT AUC values were 
significantly increased in the CFD compared to the HFD and control group (850.08 ± 71.74 
vs. 596.13 ± 53.05; p<0.0001 and 599.27 ± 131.14; p=0.003) respectively (Fig 16b).  At 
twelve months the glucose clearance following the IVGTT bolus was reduced in all three 
groups (control: 1.54 ± 1.45 vs. HFD: 1.50 ± 1.33; p =0.9621 and CFD: 1.17 ± 1.11; p =0.650) 
(Table 9).  GS-ISR at 12 months on CFD showed significantly decreased insulin secretion at 
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30 min (1.56 ± 1.40 ng/ml p<0.001) compared to HFD (5.21 ± 1.77 ng/ml) (Fig 17a).  GS-ISR 
AUC values of the CFD (175.40 ± 113.84; p=0.043) were significantly decreased compared to 
HFD (354.67 ± 135.71) (Fig 17b). 
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Figure 14a: IVGTT at three months  
Values are expressed as mean ± SD.  p>0.05 at all time points between groups.   
 
 
Figure 14b: AUC IVGTT at three months  
Values are expressed as mean ± SD.  p>0.05 at all time points between groups.   
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Figure 15a: GS-ISR at three months 
Values are expressed as mean ± SD.  p>0.05 at all time points between groups.   
 
 
Figure 15b: AUC GS-ISR at three months 
Values are expressed as mean ± SD.  p>0.05 at all time points between groups.    
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Figure 16a: IVGTT at twelve months 
Values are expressed as mean ± SD. At 3 min: CFD vs. HFD, † p=0.04; at 5 min: CFD vs. 
HFD, ††† p<0.0001 and control ** p=0.003; at 10 min: CFD vs. HFD, ††† p=0.0002 and control 
* p=0.03.    
 
Figure 16b: AUC IVGTT at twelve months 
Values are expressed as mean ± SD.  CFD vs. HFD, ††† p<0.0001 and control ** p=0.003 
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Figure 17a:  GS-ISR at twelve months 
Values are expressed as mean ± SD.  At 30 min: CFD vs. HFD, †† p=0.0047.   
 
Figure 17b:  AUC GS-ISR at twelve months 
Values are expressed as mean ± SD.  CFD vs. HFD, † p=0.043 
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Table 9: Glucose clearance rate at three and twelve months  
Values are expressed as mean ± SD.  p>0.05 in all groups compared to Control.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glucose clearance rate
12 months
Control 1.54 ± 1.45
HFD 1.50 ± 1.33
CFD 1.17 ± 1.11
3 months
Control 3.32 ± 2.72
HFD 1.15 ± 1.10
CFD 1.78 ± 1.07
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3.6 2-deoxy-[3H]-D-glucose uptake in muscle, liver and fat tissue between CFD and 
control rats 
After three months the 2-deoxy-[3H]-D-glucose uptake glucose uptake in  muscle tissue of the 
CFD fed rats was reduced compared to the controls (17821.27 ± 2682.65 vs. 26936.87 ± 
9033.56 dpm / g tissue; p=0.0008) (Fig 18).  Liver glucose uptake was similar between the 
two groups while the uptake in adipose tissue in the CFD group was reduced compared to 
controls (controls: 1386.37 ± 175.15 vs. CFD: 964.18 ± 120.00; p< 0.0001) (Fig 18). 
There were no significant differences in the 2-deoxy-[3H]-D-glucose uptake of muscle, liver or 
fat tissue between controls and CFD fed rats at twelve months (Fig 19). 
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Figure 18: 2-deoxy-[3H]-D-glucose uptake in muscle, liver and fat tissue at three 
months 
Values are expressed as mean ± SD.  Muscle: CFD vs. control, *** p=0.0008; Fat: CFD vs. 
control, *** p<0.0001.   
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Figure 19: 2-deoxy-[3H]-D-glucose uptake in muscle, liver and fat tissue at twelve 
months 
Values are expressed as mean ± SD.  p>0.05 between groups. 
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3.7 IHC staining of pancreatic sections 
3.7.1.1 Double immunolabeling for glucagon and insulin 
Double immunolabeling for glucagon and insulin revealed the typical endocrine arrangement 
of α-cells at the periphery of the islets and the more abundant β-cells in the centre of the 
islets.  Method controls Fig. 20 were employed to verify the specificity of the immunostaining. 
 
 
Original magnification x 100.    
 
Figure 20:  Photomicrographs of IHC method controls  
Low levels of non-specific background staining were detected using method controls in which 
both primary antibodies were omitted (A).  Method controls verified the specificity of glucagon 
IHC staining by omitting insulin antibody (B), and insulin specificity by omitting glucagon 
antibody (C). 
 
3.7.1.2 Islet morphology 
The islet morphology double immunostaining for insulin (red) and glucagon (brown) at three 
months showed that the islets were morphologically unaffected by the diets (Fig 21).  
However, at twelve months the islets of rats fed a HFD and CFD showed an increased 
appearance of hypertrophied irregular islets.  In the CFD fed rats, the large irregular islets 
showed an increased presence of amorphous deposits and fibrous changes (Fig 21). 
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   Original magnification x 100.    
Figure 21:  Photomicrographs of islets at three and twelve months  
IHC staining of β-cells using an anti-insulin antibody stained red and the brown staining 
indicates the α-cells demonstrated by anti-glucagon antibody binding. 
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3.7.2 Morphometrical parameters 
There were no significant differences measurable at three months on the diets compared to 
the controls.  Morphometrical parameters showed significant increases in the 
endocrine/exocrine area and body mass to β-cell/exocrine ratio of the CFD and HFD vs. 
controls at twelve months (Table 10).  The β-cell/α-cell ratio of the CFD was also increased 
compared to controls at twelve months (Table 10).   
In the HFD and CFD at twelve months the percentage of small islets (<2500 μm²) increased 
relative to the three months with a concomitant decrease in larger islets (20 001-99 999 μm²) 
(Table 11 and Fig 22a and Fig 22b).   
 
Table 10: Morphometrical parameters at three and twelve months 
 
Values are expressed as mean ± SD.  CFD vs. control, * p<0.05; HFD vs. control, * p<0.05; ** 
p<0.001. 
 
  
 Mean islet size 
(µm
2
) 
Endocrine/exoc
rine area 
 β-cell/ α-cell 
ratio 
 Body mass to 
β-cell/ exocrine 
ratio 
36493 ± 25875
37277 ± 22788
2.64 ± 1.10
10.29 ± 4.06
** 
7.45 ± 1.94
* 
2.17 ± 0.42
5.21 ± 2.37
7.10 ± 3.87
* 
1.90 ± 0.71
76331 ±  46058 0.013 ± 0.006 0.60 ± 0.08 3.68 ± 1.91
62014 ± 26175 0.012 ± 0.006 0.66 ± 0.06 4.1 ± 2.23
12 months
Control
HFD
CFD
50067 ± 17698 0.008 ± 0.003
0.011 ± 0.002
0.029 ± 0.008
*
0.029 ± 0.010
*
56913 ± 38272
 Morphometrical 
parameters
3 months
Control
HFD
CFD
0.62 ± 0.03
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Table 11: Percentage islet distribution between diets at three and twelve months 
 
Values are expressed as mean ± SD.  * vs. three months of the same islet size and diet ; † vs. 
twelve months of the same islet size and diet; * p ≤0.05; ** p ≤ 0.001; †; p ≤0.05 ;†††; 
p<0.0001.   
 
 
 
 
 
 
 
3 months 12 months 3 months 12 months 3 months 12 months
<2500 μm² 28 ± 16 33 ± 23 23 ± 8 43 ± 18 * 22 ± 10 49 ± 13 **
2501 – 7500 μm² 18 ± 7 16 ± 1 18 ± 5 20 ± 7 16 ± 6 20 ± 4
7501-12500 μm² 10 ± 2 8 ± 5 9 ± 4 8 ± 5 10 ± 2 5 ± 4 †
12501-20000 μm² 7 ± 4 7 ± 4 7 ± 5 6 ± 4 6 ± 4 5 ± 2 
20001-99999 μm²  21 ± 9 22 ± 10 28 ± 7 15 ± 7 †  32± 6 12 ± 4 †††
>100000 μm²  15 ± 9  15 ± 11 16 ± 6 8 ± 3 † 14 ± 5 9 ± 5
Control HFD CFDPercentage islet 
distribution
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Figure 22a: Percentage islet distribution at three months 
Values are expressed as mean ± SD.  † vs. twelve months of the same islet size and diet; † p 
≤0.05 ;††† p<0.0001. 
 
Figure 22b: Percentage islet distribution at twelve months 
Values are expressed as mean ± SD.  * vs. three months of the same islet size and diet * p 
≤0.05; ** p ≤ 0.001.  
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3.7.3 GLUT2 image analyses 
The staining intensity of the different diets at three months showed no difference between 
diets although at twelve months the CFD GLUT2 images appeared more intense when 
compared to the controls and HFD (Fig 23).  Scoring of GLUT2 immunohistochemical staining 
intensity by two independent blinded scorers showed that there was no difference in the 
GLUT2 staining intensity of the pancreatic islets between the diet groups at three months 
(control: 2.3 ± 0.48 vs. HFD: 2.4 ± 0.52 vs. CFD: 2.7 ± 0.48) (Table 12).  At twelve months the 
GLUT2 staining intensity of the CFD fed rats was increased compared to the controls (control: 
1.7 ± 0.67 vs. CFD: 2.6 ± 0.53, p=0.02) (Table 12). 
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Original magnification x 100. 
Figure 23: GLUT2 pancreatic immunostaining 
Plasma membrane GLUT2 of the pancreatic islets is visualized by DAB immunostaining 
(brown). 
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Table 12: Evaluation of GLUT2 staining 
 
Values expressed as mean ± SD.  CFD vs. control, * p=0.02.   
 
  
12 months
Control 1.7 ± 0.67
HFD 1.8 ± 0.79
CFD 2.6 ± 0.52 *
GLUT2 scoring
3 months
Control 2.3 ± 0.48
HFD 2.4 ± 0.52
CFD 2.7 ± 0.48
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3.7.4 MIB5 and Insulin immunostaining 
The MIB5 staining in all diets at three and twelve months was very low (< 5%) or no staining 
at all.  Few detectable MIB5 positive β-cells were observed at three months in all three groups 
although this was < 5% (Table 13).  In the CFD rats at twelve months there were also few 
positive β-cells with no detection in HFD and control rats. 
 
Table 13: Evaluation of MIB5 and insulin staining 
 
Values expressed as mean ± SD. 
 
 
 
 
 
 
 
12 months
Control 0.00 ± 0.00
HFD 0.00 ± 0.00
CFD 0.60 ± 0.55
MIB5 scoring
3 months
Control 0.60 ± 0.55
HFD 1.00 ± 0.00
CFD 0.80 ± 0.45
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3.8 Electron micrographs of CFD at twelve months  
Electron micrographs confirmed the appearance of degenerative changes in the pancreas 
tissue of rats fed CFD for twelve months also the presence of fibrous tissue, macrophages 
and inflammatory cells (Figures 24a and 24b).   
 
 
Original magnification x 2000. 
Figure 24a: Electron micrograph of a pancreatic islet at twelve months on CFD 
The presence of β-cells (left and right lower corner), areas of fibrous and the presence of 
various inflammatory cells including lymphocytes and macrophages can be seen within the 
islet.   
 
 
β-cell 
Inflammatory cells 
Macrophages 
Area of fibrosis 
71 
 
 
Original magnification x 2500. 
Figure 24b: Electron micrograph of a pancreatic tissue of CFD fed rat at twelve months  
Endocrine cells and an exocrine cell (top) with a large area of fibrosis (left) can be seen. 
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SUMMARY OF RESULTS 
Table 14: Summary of results 
 
Parameters 3 months 12 months 
HFD CFD HFD CFD 
Calorific intake ↑ ↑ ↑ ↑ 
Body weight ↑ ↑ ↑ ↑ 
RF weight ↑ ↑ ↑ ↑ 
Fasting glucose no change no change no change ↑ (controls and 
HFD) 
Fasting insulin no change ↑ ↓ (CFD and 
controls) 
↑ (HFD) 
HOMA-IR no change ↑ no change ↑ (HFD and 
controls) 
IVGTT AUC no change no change no change ↑(controls and 
HFD 
GS-ISR AUC no change no change no change ↓(HFD) 
2-deoxy-
[3H]-D-
glucose 
uptake 
muscle – ↓ – no change 
liver – no change – no change 
fat – ↓ – no change 
Mean islet size no change no change no change no change 
Endocrine/exocrine 
area 
no change no change ↑ ↑ 
β-cell/α-cell ratio no change no change no change ↑ 
Body mass to β-
cell/exocrine ratio 
no change no change ↑ ↑ 
GLUT2 no change no change no change ↑ 
MIB5/ins no change no change no change no change 
Islet morphology no change no change Hypertrophied  
irregular islets  
Large irregular 
islets, areas of 
fibrosis and 
inflammation 
All arrows indicating significance compared to controls unless stated otherwise. (↑= 
increased; ↓= decreased; – = not applicable) 
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DISCUSSION 
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Overview 
The specific diets in this study were used to compare a high-fat diet (HFD) and café diet 
(CFD), which combines a high-fat diet with the addition of sucrose/fructose to mimic a typical 
westernized diet, to a normal balanced diet (control) (Botezelli, 2010).  Western diets 
classically include refined foods with high calorific value and a high fat content (Cerf, 2007).  
In addition, the increased consumption of fructose-rich corn syrup, used as sweeteners in soft 
drinks has further exacerbated the scourge of obesity, insulin resistance (Hofmann and 
Tschöp, 2009) and the development of T2D (Huang et al, 2004).  In the USA a sharp increase 
in recent years in the incidence of metabolic syndrome and obesity has been positively 
correlated with a 30% increase in the consumption of fructose (Botezelli, 2010).  In animals a 
fructose based diet has been shown to induce similar disturbances to lipid (Botezelli, 2010) 
and carbohydrate metabolism (Huang et al, 2004).   In this study the effect of a high-fat diet in 
combination with fructose and sucrose were evaluated in Wistar rats after three months 
(mature) and twelve months (aged).  This was to access the relationship between diet and 
age in the progression of obesity, glucose intolerance, insulin resistance and T2D. 
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4.1 Diet and calorific intake 
During this study we showed that at three months the HFD and CFD fed rats consumed more 
calories than the control fed rats.  Similarly, at twelve months, the HFD and CFD calorific 
intake was increased compared to the controls. The increase in food intake between the HFD 
and CFD fed rats could be due to the increased palatability of the HFD which promotes 
hyperphagia (Cerf, 2005) consisting of moist patties compared to the controls which received 
standard laboratory chow dry pellets.  Diets high in saturated fats, palmitate, has been 
implicated as causing brain insulin resistance by a reduction in leptin and insulin signaling, 
which are important hormones responsible for the regulation of food intake (Benoit et al, 
2009).  Therefore this could possibly be the reason for hyperphagic effect of the HFD and 
CFD fed rats.  Interestingly, the HFD fed rats consumed more calories than the CFD fed rats 
at twelve months.  This was despite the increased amount of calories introduced by the 
addition of the sucrose/fructose to their drinking water.   
 
4.2 Body weight and obesity 
The increased 40% energy as fat, in the HFD and CFD, played a role in the increased body 
weight when compared to the control fed rats, which received standard diet with 10% energy 
as fat.  Studies comparing a standard diet, of approximately 10 % energy as fat, to increasing 
dietary fat content have found similar results (Kamgang et al, 2005; Krygsman et al, 2010).  At 
three and twelve months, the CFD fed rats gained more weight compared to the HFD fed rats, 
although this was not significant which suggests that the addition of sucrose/fructose to a 
HFD might have an effect on weight gain.  An evaluation of the consumption of take-away 
foods (includes foods such as pizza, burgers, fries and fried chicken) in young adults in 
Australia revealed a higher prevalence of moderate abdominal obesity when eating take-away 
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food twice a week or more which further links the  effect of high-fat diets to obesity (Smith et 
al, 2009).   
 
No intervention for energy expenditure was applied during the study therefore these rats, due 
to confinement in the cages, were submitted to a sedentary lifestyle which combined with 
high-fat feeding further exacerbated the development of obesity (Zimmet et al, 2001).   
 
As a measure of obesity, the RF pads were excised and weighed.  The measurement of this 
adipose tissue has been previously used as a measure of body fat (de Freitas Mathias et al, 
2007).   As with the body weight, the RF pads of the CFD fed rats was increased compared to 
the controls.  Similarly to body weight the CFD fed rats RF weights also slightly increased 
compared to the HFD fed rats albeit not significant.  Obesity is associated with an increased 
number of adipocytes (Thévenod, 2008) and can lead to leptin resistance (Galic et al, 2010).  
Adipocytes produce leptin which is an appetite suppresser that has been shown to be over-
produced in obese subjects (Zhang and Scarpase, 2006; Thévenod, 2008).  Overproduction 
of leptin and cytokines, such as TNF-α and IL-6, in adipose tissue can cause cellular 
resistance to insulin in the adipose tissues and can also cause insulin resistance in muscle, 
liver (Thévenod, 2008), brain (Benoit et al, 2009) and lead to T2D (Galic et al, 2010).  Leptin 
resistance promotes obesity which leads to further devastation of metabolic systems in the 
body (Zhang and Scarpase, 2006; Benoit et al, 2009).  Saturated fatty acids especially 
palmitate, has been implicated in the development of brain insulin resistance by attenuated 
insulin activity and reduced leptin signaling in the brain hereby contributing directly to obesity  
(Benoit et al, 2009).   
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 4.3 Fasting blood glucose and serum insulin concentrations 
At three months the diets had no effect on fasting blood glucose concentrations.  Suggesting 
that at three months the rats were able to compensate for the diabetogenic effects of the HFD 
and CFD.  Despite maintaining normoglycemia, serum insulin concentrations at three months 
were increased in the CFD and were slightly increased in the HFD although this was not 
significant.  Suga et al also reported substantial insulin resistance and hyperinsulinemia 
during fructose feeding after two weeks (Suga et al, 2000).  The increasing insulin 
concentrations induced by the CFD and HFD gives an early indication of a degree of insulin 
resistance.  In a similarly study sucrose and high-fat feeding for eight to nine weeks resulted 
in normoglycemia but with increased insulin concentrations (Hallfrisch et al, 1981)  Obese 
individuals may exhibit normoglycemia due to the sufficient production of insulin but suffer 
from insulin resistance in the peripheral tissues such as muscle, liver and adipose tissue 
(Sesti, 2006).  However, when the pancreas reaches its capacity to overproduce insulin this 
then leads to elevated fasting blood glucose concentrations and impaired glucose tolerance 
(Sesti, 2006; Thévenod, 2008). 
At twelve months, the CFD fed rats developed mild hyperglycemia.  The fact that the HFD fed 
rats did not develop hyperglycemia suggests that the Wistar rats were able to adapt to high-
fat feeding and that the addition of sucrose/fructose was required to produce early signs of 
glucose intolerance and T2D.  These findings further support the evidence that the addition of 
fructose enhanced sweeteners like corn syrup to food and especially soft drinks is 
contributing to obesity and T2D in humans (Bray et al, 2004; American Diabetes Association, 
ADA, 2006; Hofmann and Tschöp, 2009).  At twelve months, fasting serum insulin 
concentrations of the CFD fed rats were further increased, which, together with the 
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hyperglycemia is clinically consistent with early T2D.  In contrast the HFD and the control rats 
maintained normal insulin serum concentrations.   
 
4.4 Homeostatic model assessment of insulin resistance (HOMA -IR) 
The HOMA-IR model for the assessment of insulin resistance is commonly used as a tool for 
measuring the degree of insulin resistance.  The greater the HOMA-IR value, the greater the 
degree of insulin resistance is for that individual (Bonora et al, 2002).   
 
The HOMA-IR value of the CFD rats were increased at both three months and twelve months 
when compared to HFD and control fed rats.  A review by Stanhope and Havel revealed 
increased HOMA-IR in humans consuming fructose-rich diets (Stanhope and Havel, 2009).  
Taken together the relationship between diet, age, glucose homeostasis and insulin sensitivity 
has clearly been established in this model.  The addition of sucrose/fructose to a high-fat diet 
worsens obesity, exacerbates glucose intolerance, insulin resistance and increases the risk of 
developing T2D over time (Hofmann and Tschöp, 2009).  The relationships between fatty 
acids, obesity and insulin resistance have been well established (Boden and Carnell, 2003; 
Boden, 2006; Krygsman et al, 2010).  High concentrations of fructose also contribute to the 
development of insulin resistance.  Initially, fructose was thought to be a safe low glycemic 
index sugar for diabetes patients as fructose does not acutely raise blood glucose 
concentrations (Sánchez-Lozada et al, 2008) nor does it stimulate insulin secretion (Elliott et 
al, 2002) as β-cells lack a fructose transporter (Elliott et al, 2002; Bray et al, 2004).   Fructose 
is mainly transported into the cell by the insulin insensitive glucose transporter GLUT5 (Bray 
et al, 2004; Botezelli et al, 2010).  According to the ADA, diabetes patients should avoid the 
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use of fructose sweeteners.  However, small amounts such as present in fruits and 
vegetables, has very minimal effect on glucose metabolism as it usually only accounts for 
approximately 3-4% of energy intake (ADA, 2006).  At high concentrations, as was in our CFD 
diet most of the fructose is converted to fatty acids in the liver and this further exacerbates 
insulin resistance (Botezelli et al, 2010).  
 
4.5 Intravenous glucose tolerance test, glucose stimulated insulin secretion and 
glucose clearance rate  
Intravenous glucose administration was preferred as it elicits tissue response to glucose 
uptake particularly in muscle then liver and fat. Interference that may occur as a result of 
gastrointestinal tract glucose uptake is reduced (DeFronzo, 2004).   
At three months the respective diets had no effect on the glucose concentrations after 
glucose stimulation at any of the time points.  Similar results were obtained in a study on 
normal diet versus increasing amounts of high-fat diets over two months (Krygsman et al, 
2010).  However, the IVGTT AUC value was higher in CFD rats compared to HFD and 
controls although this was not significant.  The GCR of the HFD and CFD fed rats was also 
diminished indicating defective clearance of glucose from the circulation.   
By twelve months the CFD fed rats had increased peak glucose concentrations at 3, 5 and 10 
min after glucose stimulation.  The AUC values of the CFD fed rats increased compared to 
the HFD and control fed rats.  The GCR rates of the HFD and CFD fed rats had deteriorated 
further compared to the three month values.  These results show an age related progression 
in glucose intolerance following an IVGTT.  Similarly in a review by DeFronzo (2004) where 
rheses monkeys presented with decreased tissue sensitivity to insulin. When aged, a high 
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percentage of these monkeys developed T2D (DeFronzo, 2004).  Glucose stimulated-insulin 
secretion rates, at three months, showed a trend towards increased serum insulin peak 
values at 5 and 10 min in the CFD rats and increased AUC values when compared to HFD 
and controls.  By twelve months the GS-ISR insulin concentrations of the CFD rats were 
reduced at 30 min compared to the HFD and the control fed rats.  An overall reduction in the 
insulin response to the glucose bolus was observed over the one hour period.  As was 
reflected in the lower AUC values compared to the control and HFD fed rats.  The IVGTT and 
GS-ISR studies showed that CFD fed rats developed glucose intolerance and initial insulin 
resistance at three months.  By twelve months the diet induced affects had progressed into an 
insulin deficient response to glucose stimulation resulting in loss of glucose control.   
 
Concurring to our finding in two months old rats infused with glucose and fat emulsion in 
Wistar rats showed no effect on insulin sensitivity or insulin secretion suggesting that 
glucolipotoxicity has no effect in young Wistar rats (Fontés et al, 2010).  The same study also 
evaluated six months old rats and which showed reduced glucose-induced insulin secretion 
(Fontés et al, 2010).  
 
4.6 2-deoxy-[3H]-D-glucose uptake in muscle, liver and fat tissue 
Deoxy-glucose is taken up by tissue in the body at the same rate as glucose (Utriainen et al, 
2000).  The deoxy-glucose is however, not metabolized by the cells therefore accumulates 
intra-cellularily (Chadwick et al, 2007).  Therefore radio-active labeled 2-deoxy-[3H]-D-glucose 
can serve as a tool in measuring glucose uptake (Chadwick et al, 2007).  The route of 
glucose administration to the body also plays a major part in glucose uptake (DeFronzo, 
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2004).  During intravenous glucose administration, the majority of glucose is disposed of by 
the muscle tissues (approximately 80-90%) and to a lesser extent the liver and fat tissue 
(DeFronzo, 2004).   
 
Glucose uptake as measured by 2-deoxy-[3H]-D-glucose in the three months fed a CFD, rats 
showed reduced glucose uptake in the muscle and fat tissue.  The reduction in glucose 
uptake of muscle and fat is consistent with peripheral insulin resistance and the subsequent 
failure of these insulin sensitive tissues to clear glucose from the circulation.  By twelve 
months there were no differences in labeled glucose uptake between diet groups.  This was 
interesting, but not an unexpected finding, as with age, increasing levels of glucose 
intolerance occurs in sedentary animals (Tokuyama and Suzuki, 1998) which was 
demonstrated in decreased GCR of all three the diet groups at twelve months.  An overall 
reduction in muscle glucose uptake was observed at twelve months when compared to three 
months which further suggest an age-related decrease in glucose disposal in muscle.   
 
4.7 Islet morphometry of pancreatic tissue 
4.7.1 Immuno-labeled insulin and glucagon  
Pancreas tissue was immuno-stained for insulin and glucagon which revealed the β-cells and 
α-cells respectively.  This method was used to identify the pancreatic islets as the β-cells and 
α-cells constitute approximately 95% of the islet endocrine cells.  At three months, in terms of 
islet morphology, no diet induced effect could be observed between the groups.  At twelve 
months, however, diet had a profound effect on the morphology of especially the larger islets.  
In the HFD group, the morphological changes were limited to the larger islets that appeared 
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more irregular and lobular.  These irregularly shaped islets also showed signs of segregation 
of endocrine islet component by fibrous tissue.  In CFD group, at twelve months, these 
morphological changes were more profound with an increase in intra-islet fibrous tissue 
deposition and complete segregation of the islet into smaller sub-islets.   Furthermore the 
arrangement of the endocrine cells within these affected islets appeared to be more cord-like 
which suggest that the normal glomus like vascular arrangement was disrupted.  Although no 
morphological changes were observed at three months, morphometry revealed an increase in 
the percentage of larger islets in the HFD and CFD groups.   The increase in the proportion of 
larger islets is consistent with a diet induced hypertrophic compensatory process.  At twelve 
months, in contrast to three months, morphometry revealed that the incidence of smaller islets 
had increased.  This would suggest that the diet induced adaptive process had changed from 
a hypertrophic to hyperplastic.  Perhaps the demise of the larger islets could be partial proof 
of compensatory response by increased amount of smaller islets which could indicate new 
islet formation.  In addition, there was an increase in the islet area per pancreas and an 
increase in β-cell area per islet.  This confirms that the β-cells of the HFD and CFD rats were 
still able to adapt to the dietary and metabolic demand at twelve months.  This is a surprising 
finding as Wistar rats are regarded to be mature at two to three months and aged at 14.5 to 
15.5 months (Biagas et al, 1996) and it is generally accepted that β-cell regeneration 
diminishes with age (Bouwens and Rooman, 2006). 
 
4.7.2 Immunostaining of GLUT2 
GLUT2 immunostaining was performed on pancreas tissue of respective diets at three and 
twelve months.  Immunostaining of GLUT2 at three months revealed no significant difference 
in staining between CFD, HFD and control fed rats.  At twelve months the staining intensity 
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was reduced in the HFD and controls when compared to the three months group.  This is an 
indication that in β-cells, GLUT2 expression is regulated or affected by diet and in particular 
our CFD fed rats.  This finding is in line with a study by Gouyon et al, 2003, where massive 
recruitment of GLUT2 occurs upon ingestion of a simple sugar rich meal.    
 
4.7.3 Double immuno-labeling of MIB5 and insulin 
MIB5/Insulin double-immunolabeling was also performed on pancreatic sections from the 
diets to detect proliferating β-cells which stain positive for both MIB5 and insulin.  In this study 
very few MIB5/insulin positive β-cells were detected with no significant difference among all 
diet groups at three and twelve months of the study.  However, the CFD fed rats showed a 
non-significant increase in proliferating β-cells in comparison to the control diet rats at three 
and twelve months.  This further supports the findings that in Wistar rats β-cell adaptation to 
dietary stimulation occurs for up to twelve months.   
 
4.8 Electron microscopy 
Electron microscopy confirmed the light microscopical observations and in addition revealed 
the presence of an active inflammatory process with the presence of lymphocytes and 
macrophages laden with residual bodies.  The presence of these inflammatory cells, usually 
characteristic of T2D, together with the islet fibrous changes is suggestive of chronic 
inflammation (de Koning et al, 2008).  It is of interest that the changes were limited to the 
larger islets.  The logical conclusion would be that these islets are older and therefore have 
been subjected to the diet for a longer period or they have been more active and therefore 
more susceptible to oxidative stress.  Taken together the morphological changes and the 
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presence of inflammatory processes are consistent with T2D (Zozulinska and Wierusz-
Wysocka, 2006). 
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CONCLUSION 
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CONCLUSION 
High-fat diet fed to Wistar rats increased body weight and lead to increased abdominal 
adiposity.  The addition of sucrose/fructose to a high-fat diet exacerbated insulin resistance 
and glucose intolerance.  The dietary period (three or twelve months) together with ageing of 
the rats further contributed to the advancement of insulin resistance to hyperglycemia.  In 
agreement with other studies, the twelve months HFD and CFD fed rats did not present with 
overt signs of T2D.  However, in this study at twelve months morphological changes in the 
larger islets were consistent with the development of T2D.  Interestingly, despite the 
degenerative changes in the larger size islets of the HFD and CFD fed rats, there was an 
increase in the proportion of small islets.  This would suggest that despite long-term insulin 
resistance, glucose intolerance and reduced peripheral glucose disposal, β-cell compensatory 
mechanism/s still occurred in aged Wistar rats.   
 
SHORTCOMINGS AND FUTURE PROSPECTS 
Palatability of dry pellets and moist patty diets should be considered in future study design 
and dry pellets substituted by moist patties.  
The use of metabolic cages for determination of twenty four hour urine and stool production, 
and food and water intake.   Analysis of biochemical electrolytes in the urine can be 
measured (e.g. ketones, urea and creatinine).   
The pancreas was not weighed therefore parameters such as β-cell mass could not be 
determined.   
Liver should be assessed for histopathological changes associated with T2D such as 
steatosis and fibrosis.   
Demonstrate β-cell apoptosis using antibodies such as BAX, caspase3 or tunnel.  
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Determine serum free fatty acid profile thereby establishing the effect of specific free fatty 
acids on insulin resistance.  Assess inflammatory status of the rats like TNF-α and IL-6 using 
enzyme-linked immunosorbent assays (ELISA). 
To determine the dietary effect on insulin signaling in muscle, liver and fat thereby 
establishing a molecular basis for the insulin resistance. 
Ex-vivo studies on isolated β-cells to assess the functional capacity of the islets following 
dietary insult. 
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